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SUMMARY 
The inducible costimulator (ICOS), a member of the CD28 family of 
costimulatory molecules, is rapidly induced upon T cell activation. Although the critical 
role of ICOS in T-cell-mediated immunity is well documented, little is known of the 
intracellular pathways that modulate ICOS expression. We first investigated ICOS 
induction during early activation of T cells by T cell receptor (TCR) and CD28 co-
engagement. We found that the ectopic expression of the transcription factor NFATc2 or 
a constitutively active form of MEK2 that activates ERK amplified icos transcription by 
acting on a 288-bp region of the icos promoter in luciferase reporter assays. We also 
identified a site on the promoter that is sensitive to ERK signalling and further showed 
the in vivo binding of NFATc2 to the promoter, the intensity of which is diminished when 
Fyn signalling is ablated. The normal activation of ERK but reduced nuclear 
translocation of NFATc2 in Fyn-deficient (Fyn-/-) CD4+ T cells imply that Fyn and 
NFATc2 act in a common axis, separate from ERK, to drive icos transcription. 
Following initial activation, T cells differentiate into Th1 or Th2 cells, depending 
on the nature of the immune response. Because ICOS expression was found to be 
differentially expressed in these cells, we next examined the control of ICOS expression 
by Th1-specific T-bet and Th2-specific GATA-3, which drive respective lineage 
commitment, as well as NFATc2, which is broadly expressed across lineages. We 
observed that the over-expression of T-bet or GATA-3 could enhance, and NFATc2 
could further synergize with either of them to increase, icos transcription. While T-bet 
acted on the icos promoter, GATA-3 operated via an icos 3′UTR element. Interestingly, 
NFATc2 was found to bind promiscuously the icos promoter in developing Th0, Th1 and 
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Th2 cells but became selectively associated with T-bet at the promoter and with GATA-3 
at the 3′UTR in fully differentiated Th1 and Th2 cells, respectively. The binding 
dynamics of these transcription factors coincided with the chromatin accessibility of 
these regulatory regions in the different Th cells as assessed by histone trimethylation. 
Finally, we also found ICOS expression to be regulated at the post-transcriptional 
level by a recently discovered RING-type E3 ubiquitin ligase, roquin. Enforced 
expression of wild-type but not a sanroque mutant form of roquin accelerated the decay 
of ICOS mRNA in a T cell line. Collectively, our findings indicate that during the initial 
TCR/CD28-mediated activation of T cells, Fyn-calcineurin-NFATc2 and MEK2-ERK1/2 
signalling pathways cooperate to induce ICOS expression. As Th cells differentiate along 
the Th1 or Th2 lineage, the non-selectively expressed NFATc2 synergises with Th-
restricted T-bet or GATA-3 in a temporally evolving fashion to direct icos transcription 
via distinct regulatory elements in Th cells undergoing differentiation. In addition to the 
transcriptional control of ICOS expression in Th cells, there exists a post-transcriptional 
level of ICOS regulation, in terms of mRNA turnover, mediated in part by the ROQ 
domain of roquin. 
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1.1 Two-signal model of T cell activation 
Mounting an appropriate immune response depends on the careful regulation of 
lymphocyte activation. To this end, lymphocytes require two independent signals to 
become optimally activated. The first, an antigen-specific signal is sent via the unique 
antigen receptor: TCR on T cells or surface Ig on B cells. The TCR is cross-linked by an 
agonist peptide or antigen (Ag) presented in the context of the major histocompatibility 
complex (MHC) II for cluster of differentiation (CD)4+ and MHC I for CD8+ T cells on 
the surface of antigen presenting cells (APCs), which include macrophages, dendritic 
cells (DCs) and B cells. The second signal, termed costimulation, is critical for full 
activation, sustaining cell proliferation, inducing differentiation and preventing anergy 
and/or apoptosis (Frauwirth and Thompson, 2002; Chambers and Allison, 1997; 
Chambers, 2001), and in the context of T cells, is delivered by costimulatory ligands 
expressed on activated APCs (Coyle and Gutierrez-Ramos, 2001; Sharpe and Freeman, 
2002; Greenwald et al., 2005) (Figure 1.1). The two most prominent superfamilies 
mediating costimulation are those of B7/CD28 (Carreno and Collins, 2002; Lenschow et 
al., 1996b; Shahinian et al., 1993) and tumour necrosis factor / receptor (TNF/TNFR) 
(Croft, 2003a; Croft, 2003b), the signals of which are in turn negatively regulated by 
inhibitory receptors expressed upon lymphocyte activation. Members of the CD28 family 
of receptors, part of the broader immunoglobulin (Ig) superfamily, are type I 
transmembrane glycoproteins and share 20 – 35% identity in their amino acid sequences 
(Table 1.1). Despite such low homology in primary amino acid composition, these 












Figure 1.1 Two-signal model of T cell activation. 
 
Table 1.1 Comparison of CD28 family of receptors. 
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domains. Four cysteine residues, which are involved in the formation of the disulfide 
bonds of the Ig V and Ig C domains, are well-conserved. The receptors for the B7 family 
are members of the CD28 family, and possess a single Ig V-like extracellular domain. 
Their cytoplasmic tails contain putative Src homology (SH)2- and SH3-motifs thought to 
be involved in signal transduction (Rudd and Schneider, 2003; Wang and Chen, 2004). 
APC-expressed B7-1 (CD80) and B7-2 (CD86) bind the costimulatory CD28 and 
inhibitory cytotoxic T lymphocyte-associated antigen (CTLA)-4 on T cells. Engagement 
of the prototypical CD28 receptor on naïve T cells by either B7-1 or B7-2 augments the 
TCR signal (Riley and June, 2005), which leads to enhanced interleukin (IL)-2 
transcription (Civil and Verweij, 1995), expression of CD25 (IL-2Rα), and entry into cell 
cycle (Parry et al., 2003). Critical survival, as distinct from proliferation, signals are also 
conferred via the B-cell lymphoma (Bcl)-XL pathway (Burr et al., 2001; Okkenhaug et 
al., 2001; Sperling et al., 1996; Boise et al., 1995; Marinari et al., 2004). In contrast, the 
engagement of CTLA-4 delivers negative signals, which inhibit IL-2 synthesis, cell cycle 
progression and terminate T cell responses. 
 
1.2 Fyn and Lck signalling downstream of TCR 
The src-family tyrosine kinases p59fyn (Fyn) and p56lck (Lck) are expressed in T 
cells and constitute the most proximal signalling molecules to be activated downstream of 
TCR. They are responsible for the initial tyrosine phosphorylation of the receptor, leading 
to the recruitment of the zeta-associated protein of 70 kD (ZAP-70) tyrosine kinase, as 
well as the subsequent phosphorylation and activation of ZAP-70, linker for activated T 
cells (LAT), and phospholipase C-gamma1 (PLC-γ1), leading to calcium flux, activation 
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of calcineurin and dephosphorylation and nuclear translocation of the nuclear factor of 
activated T cells (NFAT). Although closely related, these signalling molecules have 
distinct functions during development, maintenance and activation of peripheral T cells. 
For example, during thymopoiesis, albeit Fyn can substitute for a subset of signals which 
Lck is uniquely able to provide for pre-TCRβ selection, Fyn is largely dispensable for 
gross T cell development (Appleby et al., 1992). In naïve peripheral T cells, either Lck or 
Fyn can transmit TCR-mediated survival signals, and yet only Lck is able to trigger TCR-
mediated expansion signals under lymphopenic conditions. Stimulation of naïve T cells 
to proliferate and produce IL-2 by antigenic stimuli is also severely compromised in the 
absence of Lck, but hardly impaired by the absence of Fyn. Interestingly, more profound 
defects in the Lck-dependent signalling pathway were observed with stimulation of Fyn-
deficient T cells with anti-CD3 and anti-CD28 antibodies, which was rescued by 
coaggregation of CD3 and CD4 (Sugie et al., 2004). This suggests that Fyn positively 
regulates Lck when stimulation of CD4+ T cells is restricted to TCR with no involvement 
of MHCII and CD4 co-receptor. 
Another study, examining the ability of Fyn to mediate TCR signal transduction 
in an Lck-deficient Jurkat T-cell line (JCaM1), found that the signalling leukocyte protein 
of 76 kD (SLP-76) adapter protein, the Ras mitogen-activated protein kinase (MAPK) 
and the phosphatidylinositol 4,5-biphosphate signalling pathways, but not NFAT and IL-
2 production, were activated in the absence of Fyn (Denny et al., 2000). This indicates 
Fyn mediates an alternative form of TCR signalling which is independent of ZAP-70 
activation and imply which Src family kinase is used to initiate signalling may dictate the 
outcome of TCR signal transduction, at least in human T cells. 
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1.3 CD28 costimulatory receptor 
CD28, being constitutively expressed, is critical for the activation of naive T cells 
and plays an important role in the initial phase of an immune response, while not being as 
effective in regulating effector and memory T cell responses. Despite its status as a key 
costimulatory molecule, CD28 does not account for all costimulatory functions in T cells. 
Immune responses are not totally nullified in the absence of CD28 because mice lacking 
CD28 exhibit normal Th cell activation and are able to produce IgG in response to 
infections by some viruses (Whitmire and Ahmed, 2000). In addition, priming of T helper 
(Th) cells, Ig class switching and IgM responses are reportedly normal in CD28-deficient 
mice (Wu et al., 1998), while memory Th2 effector cells can develop in the absence of 
B7-1/2 and CD28 interactions, after sensitisation with an intestinal nematode parasite 
Heligmosomoides polygyrus (Ekkens et al., 2002). Reactivation of antigen-experienced 
memory and effector T cells are far less dependent than naive T cells on CD28/B7 
costimulation (London et al., 2000), consistent with the idea that CD28 signalling is less 
important for the function of the former population of T cells. CD28 deficiency 
paradoxically promotes the development of diabetes in the nonobese diabetic (NOD) 
mouse strain (Lenschow et al., 1996a), although this observation was later attributed to 
the profound decrease of immunoregulatory CD4+CD25+ T cells in CD28-deficient 
NOD mice. Another study found that the production of effector cytokines such as 
interferon (IFN)-γ and IL-4 can be stimulated to normal levels by APCs lacking both B7-
1 and B7-2 (Schweitzer et al., 1997). Furthermore, naive TCR-transgenic T cells lacking 
CD28 are able to initiate a primary Ag-specific response, but fail to sustain proliferation 
as the cells acquire effector status (Lucas et al., 1995). This is possibly due to 
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compensation for costimulatory requirement by prolonged TCR signalling (Acuto and 
Michel, 2003), made obvious in the case of T cells genetically engineered to express a 
TCR transgene, and/or functional substitution for CD28 by other costimulatory 
molecules. These results suggest that other molecules can compensate for the absence of 
CD28 signalling. 
 
1.4 Inducible costimulator (ICOS) receptor 
1.4.1 ICOS structure and signalling 
One such recently discovered candidate belonging to the CD28 family is the 
inducible costimulator or ICOS. Alternatively termed activation-inducible lymphocyte 
immunomodulatory molecule (AILIM), the rat ICOS homologue (Tamatani et al., 2000; 
Tezuka et al., 2000), or H4 (Buonfiglio et al., 2000), ICOS is a T-cell specific molecule 
structurally and functionally related to CD28 and shares 30% to 40% sequence similarity 
to CD28 and CTLA-4 but does not carry the conserved MYPPPY motif necessary for 
binding B7-1 and B7-2 (Beier et al., 2000; Hutloff et al., 1999) (Table 1.1). Murine, rat 
and canine ICOS share respectively 71.7% (Mages et al., 2000), 67% (Tamatani et al., 
2000) and 79% (Lee et al., 2004b) sequence identities with their human counterpart. It is 
rapidly induced on T cells upon activation and binds its cognate ligand B7-H2 (also 
known as GL50 (Ling et al., 2000), B7RP-1, B7h, LICOS or ICOSL) which is expressed 
constitutively on APCs, including B cells and macrophages, and can be induced in 
cultured fibroblasts and non-lymphoid tissues by treatment with inflammatory agents 
such as LPS and TNF-α (Liang and Sha, 2002; Swallow et al., 1999). LICOS was first 
identified as the homologue of B7-1 expressed by chicken macrophages and of 
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mammalian B7-H2 and may be the contemporary form of a primordial vertebrate 
costimulatory ligand (Brodie et al., 2000). 
Similar to CD28 signalling, ICOS engagement costimulates T cell proliferation, 
promotes Th differentiation and production of IFN-γ, TNF-α, IL-4, IL-5, IL-10 and IL-13 
(Beier et al., 2000; Coyle et al., 2000; Nurieva et al., 2003b; Vieira et al., 2004; 
Yoshinaga et al., 1999) but unlike CD28, it does not enhance IL-2 production, as ICOS 
blockade did not attenuate IL-2 secretion by mice administered superantigen (SAg) 
(Gonzalo et al., 2001a). However, ICOS strikingly potentiated secretion of IL-2, IFN-γ 
and TNF-α, but not IL-4 in human naive CD4+ T cells stimulated through CD3 and 
CD28 (Mesturini et al., 2006), alluding to differences between mouse and human ICOS 
signalling. It has been suggested that ICOS signalling may be more important for 
regulating activated, effector and memory T cells (Coyle et al., 2000), whereas CD28 
functions to prime naive T cells, given its absence or very low levels of expression on 
naive T cells and its up-regulation upon stimulation in both CD4+ and CD8+ effector T 
cells (Beier et al., 2000; Tafuri et al., 2001; Yoshinaga et al., 1999). Consistent with this 
view, delayed ICOS blockade during chronic allograft rejection, the progression of which 
is mediated by effector/memory T cells, was associated with down-regulation of local 
intragraft expression of several cytokines and chemokines (Kashizuka et al., 2005). 
Blocking ICOS on effector T cells during the efferent phase of the immunopathogenesis 
of murine experimental autoimmune encephalomyelitis (EAE) abrogated disease 
(Rottman et al., 2001). Similar blockade during the effector phase of murine experimental 
autoimmune uveoretinitis ameliorated disease, while doing so during the induction phase 
had no significant effect (Usui et al., 2006b). Moreover, ICOS/B7-H2 interactions were 
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shown to play an important role in controlling the entry of effector/memory T cells across 
the endothelium into inflamed tissues in the periphery via activating the PI3-kinase/Akt 
and Rho family cascades (Nukada et al., 2006; Okamoto et al., 2004a). 
Initial characterisation of either ICOS or B7-H2 deficient mice revealed a primary 
phenotype of severe defects in germinal centre (GC) formation and B cell 
immunoglobulin class switching. (Dong et al., 2001a; McAdam et al., 2001; Tafuri et al., 
2001; Wong et al., 2003; Dong et al., 2001b). ICOS deficient mice were highly resistant 
to clinical experimental autoimmune myasthenia gravis development, exhibited defective 
T cell-mediated humoral immunity, and had a diminutive GC reaction in secondary 
lymphoid tissues (Scott et al., 2004). Consistent with the pivotal role of ICOS in GC 
development, ICOS has been implicated in the maintenance of CXCR5+ follicular B 
helper T cells (TFH) in vivo (Akiba et al., 2005). Murine ICOS deficiency is associated 
with a severe reduction of CXCR5+CD4+ GC Th cells (Bossaller et al., 2006). Human 
ICOS deficiency, on the other hand, results in a clinical phenotype indistinguishable from 
the monogenic disease known as adult-onset common variable immunodeficiency 
(Grimbacher et al., 2003; Warnatz et al., 2005). In the context of viral and parasitic 
infections, ICOS regulates CD28-dependent and CD28-independent CD4+ T cell subset 
polarisation but not cytotoxic T lymphocyte responses (Bertram et al., 2002; Kopf et al., 
2000; Loke et al., 2005). In addition, a recent study demonstrated a critical role for ICOS 
costimulation in immune containment of pulmonary influenza virus infection 
(Humphreys et al., 2006). Substantial similarity between the immune phenotype and 
responses of ICOS and B7-H2 deficient mice (Dong et al., 2001a; Mak et al., 2003; 
McAdam et al., 2001; Tafuri et al., 2001; Wong et al., 2003), combined with interaction 
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studies using recombinant protein (Nurieva et al., 2003b; Swallow et al., 1999), brought 
about the notion of a monogamous receptor-ligand relationship between ICOS and B7-
H2. So far, there has been a paucity of evidence to suggest otherwise. 
ICOS expression is optimally induced when both TCR and CD28 are activated, 
whereas its up-regulation is significantly reduced in the absence of CD28/B7 interaction 
(Coyle et al., 2000; McAdam et al., 2000), although physiologically relevant levels of 
ICOS are expressed on T cells subjected to submitogenic stimulation with anti-CD3 
antibody (Ab) (McAdam et al., 2000; Yoshinaga et al., 1999). It is therefore anticipated 
that one of the possible reasons behind attenuated ICOS/B7-H2 signalling in CD28 KO 
mice is defective ICOS up-regulation. To address the issue of the costimulatory capacity 
of ICOS in the absence of CD28, mice doubly deficient in CD28 and ICOS were 
generated and their Ab responses against environmental Ags, T-dependent protein Ags, 
and vesicular stomatitis virus were compared with those of CD28 deficient and wild-type 
(WT) counterparts. Doubly deficient mice manifested profound defects in their immune 
responses that far exceeded those observed in CD28 deficient mice, suggesting that in the 
absence of CD28, ICOS assumes the major T cell costimulatory role for humoral immune 
responses (Suh et al., 2004). Besides its dominant role in humoral immunity, ICOS 
signalling is also involved in the proliferation of effector T cells, driving the initial clonal 
expansion of primary and primed Th1 and Th2 cells in response to immunisation (Smith 
et al., 2003). Furthermore, its signalling regulates DC-mediated clonal expansion of 
human Th2, but not Th1 cells (Vieira et al., 2004), and dictates the expansion of polarised 
Th subsets developed in response to infection with Trichuris muris or Toxoplasma gondii 
(Wilson et al., 2006). 
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1.4.2 ICOS in Th1 and Th2-associated immunity 
After engagement of the T-cell receptor (TCR) by the appropriate peptide-MHC 
complex, naïve CD4+ T cells residing in peripheral lymphoid organs undergo 
differentiation into the canonical Th1 or Th2, or the more recently characterised IL-17-
producing T helper (Th17) or regulatory T (Treg) cell subsets (Reinhardt et al., 2006; 
Murphy and Reiner, 2002). It is increasingly appreciated that CXCR5+ TFH cells 
constitute a lineage distinct from Th1 or Th2 cells, although the presence of IFN-γ- and 
IL-4-producing Th cells in the follicles obscures the unique identity of these cells 
(Chtanova et al., 2004). Which lineage program is adopted by the naïve Th cell depends 
on the nature of the pathogen activating effector immune or immunomodulatory 
responses. In host defence, effector Th1 cells are responsible for cell-mediated immunity, 
providing protection against intracellular pathogens such as some bacteria, viruses and 
protozoa, whereas Th2 cells are responsible for extracellular immunity associated with 
protection against parasitic helminths (Liu et al., 2004). Both subsets have also been 
implicated in pathological responses. The very recently identified Th17 rather than Th1 
cells have been shown to mediate several organ-specific autoimmune diseases. Several 
lines of evidence indicate that Th1 cells (and IFN-γ) are actually anti-inflammatory in 
some mouse models of autoimmunity. For example, IFN-γ-deficient mice were more 
susceptible to EAE due to exacerbated expansion of encephalitogenic CD4+ T cells (Chu 
et al., 2000) and deficiency in IL-12 signalling worsened collagen-induced arthritis 
(Murphy et al., 2003). Th2 cells, on the other hand, are involved in asthmatic and allergic 
responses. The final composition of the Th cell response to antigen can therefore 
potentially determine the outcomes of inflammatory, infectious or autoimmune 
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responses, resulting in beneficial resolution of the disease or its harmful protraction and 
consequent bystander damage to the host. 
Numerous studies define an apparent role for ICOS in determining the 
polarisation of Th function, with early reports linking ICOS preferentially to Th2-type 
responses. Indeed, ICOS-deficient T cells exhibited defects in Th2 cytokine secretion 
(Dong et al., 2001a; Tafuri et al., 2001), being selectively impaired in IL-4 production 
after in vitro differentiation or in vivo priming by protein antigen (Dong et al., 2001a). In 
agreement with this, normal IL-5-mediated lung eosinophilic infiltration but defective 
IL-4-dependent IgE production were observed in ICOS-deficient mice that developed 
asthma, a Th2-type condition (Dong et al., 2001a). Using TCR transgenic mice subjected 
to the same asthma model, another study reported that monoclonal antibody (mAb)-
mediated neutralisation of ICOS signalling diminished both eosinophilic inflammation 
and IgE production (Gonzalo et al., 2001b). Consistent with this, ICOS blockade was also 
reported to inhibit Th2 effector function, although not Th2 differentiation, in a model of 
allergic airway disease (Tesciuba et al., 2001). Moreover, treatment with a blocking anti-
ICOS Ab strongly suppressed Th2-type chronic graft versus host disease (GVHD) 
(Ogawa et al., 2001), and resulted in decreases in TNF-α, IL-4 and IL-5 and total serum 
IgE levels induced by the gastrointestinal helminth Trichinella spiralis, although the 
expulsion of adult parasites was unaffected (Scales et al., 2004). As opposed to driving 
Th2-associated immunopathology, the ICOS/B7-H2 pathway surprisingly facilitated the 
development and inhibitory function of IL-10-producing Tregs important in respiratory 
tolerance and in down-regulating pulmonary inflammation in airway hypersensitivity 
(Akbari et al., 2002). More recently, in vitro Th polarisation experiments demonstrated 
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that ICOS transcriptionally costimulates Th2 differentiation by an IL-4-driven 
mechanism involving the transcription factors NFATc1 and c-Maf (Nurieva et al., 
2003a). 
Despite structure-function analyses that associate ICOS signalling with Th2 
differentiation (Andres et al., 2004; Rudd and Schneider, 2003), various in vivo infection, 
autoimmune, hypersensitivity and transplantation models suggest that ICOS could also be 
important in controlling Th1-mediated responses. Anti-ICOS therapy profoundly reduced 
both chronic and Th1-dependent acute allograft rejection (Ozkaynak et al., 2001). In a 
mouse model of cardiac allograft transplantation, delayed ICOS blockade prolonged graft 
survival while early blockade produced a reciprocal effect (Harada et al., 2003). B7RP-1-
Fc chimaeric protein stimulated Th1-dominated contact hypersensitivity when given near 
either the time of sensitisation or challenge with oxazolone (Guo et al., 2001). 
Furthermore, neutralisation of the ICOS/B7-H2 pathway respectively exacerbated or 
ameliorated disease during the sensitisation or established phases of EAE (Rottman et al., 
2001), and effectively inhibited anti-nucleolar autoantibodies and total serum IgE 
production in a mouse strain susceptible to mercury-induced autoimmunity (Zheng et al., 
2005). Blockade of the ICOS pathway increased susceptibility of CD28-deficient mice to 
Th1-type Toxoplasma gondii infection. Administration of anti-B7-H2 mAb before the 
onset of renal disease significantly delayed the onset of proteinuria, prolonged survival, 
effectively inhibited all subclasses of IgG autoantibody production and accumulation of 
both Th1 and Th2 cells during the pathogenesis of murine lupus nephritis (Iwai et al., 
2003). Blocking ICOS on the surface of CD28-deficient Th1 cells abrogated development 
of murine colitis, whereas blocking CD28 or ICOS alone had almost no effect on disease 
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induction, suggesting that CD28 and ICOS collaborate to promote colitic development by 
aggressor Th1 cells (de Jong et al., 2004). In conclusion, blockade of the ICOS/B7-H2 
costimulatory pathway affects both Th1 and Th2 responses, although the effect is more 
pronounced in highly polarised Th2 responses. 
As further confirmation of the context-dependent association of ICOS with Th 
polarisation, a study found that ICOS+CD4+ Th cells expressed strikingly different 
cytokines depending on the type of infection encountered, the chronicity of the immune 
response, and the cells' anatomical localisation. In Th2-dominated immunity against 
Schistosoma mansoni, ICOS expression of hepatic CD4+ cells was strongly associated 
with IL-5, IL-10 and IL-13 expression, but not with the chemokine receptor CXCR5, a 
pattern reflective of Th2 effector cells. However, in the secondary lymphoid organs of 
schistosome-infected mice, ICOS expression was randomly correlated with Th2 
cytokines, but positively correlated with CXCR5 expression, the hallmark of TFH cells. 
During infection with Toxoplasma gondii and in the severe combined immunodeficiency 
(SCID)-transfer colitis model, ICOS expression was positively correlated with IFN-γ 
production (Bonhagen et al., 2003). A separate study observed that ICOSlow T cells in 
unchallenged mice were loosely associated with IL-2, IL-3, IL-6 and IFN-γ; ICOSmedium 
cells with the Th2 cytokines IL-4, IL-5, and IL-13, and ICOShigh cells with the anti-
inflammatory cytokine IL-10 (Lohning et al., 2003). Consistent with the specific link 
between T cells highly expressing ICOS and IL-10 synthesis, interaction of ICOS on 
human effector T cells with B7-H2 on mature DCs strongly and selectively promoted 
IL-10 secretion (Witsch et al., 2002). 
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1.4.3 ICOS in immune tolerance 
Although the ICOS/B7-H2 pathway is extremely important for costimulating 
effector T cell responses and T cell-dependent B cell responses, it also plays a critical 
role in regulating T cell tolerance primarily through promoting Treg (especially the IL-10-
producing subpopulation) cell development, homeostasis and/or function (Greenwald et 
al., 2005), corroborated by evidence derived from several studies summarised below. 
Firstly, ICOS deficient mice were found to have decreased numbers of FoxP3+ Tregs and 
impaired in vitro Treg suppressive function compared with WT mice, leading to enhanced 
atherosclerosis (Gotsman et al., 2006). Secondly, in a mouse model of myelin 
oligodendrocyte glycoprotein (MOG) peptide-induced oral tolerance, CD4+ T cells from 
MOG-fed WT mice could not transfer suppression to ICOS deficient recipients, 
suggesting again that ICOS may have a direct role in controlling the effector functions of 
Tregs (Miyamoto et al., 2005). Thirdly, the ICOS/B7-H2 pathway was essential for the 
induction of inhalation tolerance after sensitisation with a mucosal allergen, aerosolised 
OVA, albeit redundant for the generation of Th2 responses (Gajewska et al., 2005). 
Fourthly, the development and ability to inhibit allergen-induced airway hyperreactivity 
of IL-10-producing Treg cells required T cell costimulation by mature pulmonary DCs via 
the ICOS/B7-H2 pathway. Treg cells, through the ICOS/B7-H2 signalling axis, 
downregulate pulmonary inflammation and maintain respiratory tolerance in asthma 
(Akbari et al., 2002). A fifth study exploring the relationship between expression levels 
of self-antigen and the function of self-reactive T cells in the periphery concluded that 
IL-10-producing Treg cells developed when self-antigen expression is sufficiently high 
and exert self-tolerance via ICOS signalling (Kohyama et al., 2004). Moreover, Treg cells 
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operating within prediabetic lesions to keep them from destructive progression are 
correlated with significantly higher levels of IL-10 and ICOS expression than their lymph 
node counterparts (Herman et al., 2004). Findings with an EAE-induced model of 
mucosal tolerance were similar (Miyamoto et al., 2005). Interestingly, two independent 
studies provided evidence that only maturing human plasmacytoid DCs (pDCs) as 
opposed to myeloid DCs (mDCs) up-regulated ICOSL expression to high levels, 
endowing them with the ability to promote the differentiation of naive CD4+ T cells to 
IL-10-producing Treg cells (Ito et al., 2007; Janke et al., 2006). 
 
1.5 Th1 or Th2 cell lineage decision primed by TCR and CD28 signalling 
The first echelon of signalling that activates alternate cytokine fates to prime 
naïve Th cells to differentiate into a particular lineage involves the strength and quality of 
the TCR and costimulatory signals. Accumulating evidence implicates nuclear factor 
binding the immunoglobulin κ light chain enhancer in B cells (NF-κB) and extracellular 
signal-regulated kinase (ERK) cascades in modulating TCR signal strength. The level of 
ERK activity at the early phase of naïve Th cell stimulation appears to be critical for 
deciding in part the Th differentiation outcome. Transient ERK activation due to weak 
engagement of TCR by low concentrations of cognate peptide induced IL-2-dependent 
signal transducer and activator of transcription (STAT)-5 phosphorylation, IL-4-
independent early GATA-3 expression, and IL-4 production, which were abolished by 
high-affinity TCR signalling that induced sustained ERK activation and subsequent Th1 
differentiation (Yamane et al., 2005). In developing Th2 cells, pharmacological inhibition 
of ERK decreased GATA-3 protein levels through promoting GATA-3 degradation by 
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the ubiquitin-proteasome pathway (Yamashita et al., 2005). Furthermore, ERK signalling 
facilitates GATA-3-mediated chromatin remodelling at Th2 cytokine gene loci. Another 
important family of transcription factors triggered by TCR signalling is the NFAT family, 
which are key regulators of inducible gene expression in the immune system. Upon TCR 
stimulation, NFAT members undergo calcineurin-mediated dephosphorylation and 
translocate to the nucleus where they cooperate with the activator protein (AP)-1 complex 
to activate target genes such as IL-2. Without their transcriptional partners, NFAT alone 
binding to gene promoters results in T cell anergy (Rao et al., 1997). Interpreting the role 
of NFAT members in Th differentiation is more confounding. Naive Th cells doubly 
deficient in NFATc2 and NFATc3 intrinsically differentiate into Th2 cells, even in the 
absence of IL-4 production (Rengarajan et al., 2002). Such an observation is perhaps not 
surprising, considering the fact that NFAT regulates the expression of a plethora of 
cytokines that influence Th development, including partnering with T-bet and GATA-3 to 
drive IFN-γ and IL-4 transcription respectively. 
 
1.6 Molecular circuitry of Th1 and Th2 cell differentiation programs 
Extensive work in the last decade has uncovered a complex and highly plastic picture of 
the interplay between the polarising cytokines and the transcriptional apparatus 
responsible for instructing the Th differentiation program (Rao and Avni, 2000; Glimcher 
and Murphy, 2000; Dong and Flavell, 2000) (Figure 1.2). The signature cytokines IL-12 
and IL-4 are known to promote respectively the development of Th1 and Th2 cells by 
causally inducing transcription factors such as STAT4 and STAT6 respectively, leading 
to lineage-selective gene expression (Ho and Glimcher, 2002). In the same regard, the 
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T-box transcription factor expressed in T cells (T-bet) has been shown to direct Th1 
lineage commitment (Szabo et al., 2000; Szabo et al., 2002; Szabo et al., 2003), inducing 
both transcriptional proficiency of the Ifnγ locus and responsiveness to IL-12-transduced 
growth signal (Mullen et al., 2001). These events establish an IFN-γ/STAT1 autocatalytic 
and autocrine loop to further enhance T-bet expression in the developing Th1 cell. T-bet 
in turn induces the expression of IL-12Rβ2, leading to acute IFN-γ transcription by 
potentiating the IL-12/STAT4 pathway (Afkarian et al., 2002; Mullen et al., 2001). The 
crucial importance for T-bet in the development Th1-mediated responses in vivo is 
underscored by the susceptibility of T-bet-deficient mice to Leishmania major infection 
(Szabo et al., 2002) and their predisposition to asthma (Finotto et al., 2002). On the other 
hand, the zinc finger transcription factor GATA-3 is a master regulator of Th2 
differentiation, being both necessary and sufficient to drive development of this subset 
(Zheng and Flavell, 1997), although the b-ZIP (basic-region leucine-zipper) transcription 
factor c-Maf initially skews naïve Th cells toward a Th2 phenotype via early induction of 
IL-4 (Ho et al., 1996). This precipitates an IL-4/STAT6 pathway which rapidly stimulates 
GATA-3 expression to a high level in committed Th2 cells. Whereas embryonic lethality 
caused by germline disruption of the GATA-3 gene precludes direct assessment of the 
role of GATA-3 in T cell development and Th2 differentiation (Kuo and Leiden, 1999), 
conditional deletion of GATA-3 in CD4+ T cells diminished Th2 differentiation, 
eliminated Th2 responses and allowed the generation of IFN-γ-producing cells in mutant 
compared to WT mice challenged with Nippostrongylus brasiliensis (Zhu et al., 2004). 
Moreover, sound biochemical evidence exists for GATA-3 specifying transcriptional 















































Figure 1.2 Cytokines and transcriptional apparatus governing Th1 and Th2 
differentiation. 
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and IL-13 (Lee et al., 2001; Lee et al., 2000). It is now generally accepted that a dualistic 
view of Th development is overly simplistic, partly because many complexities underlie 
the crosstalk between master regulators of this process. For example, Itk-mediated 
phosphorylation of T-bet facilitates its physical interaction with GATA-3, sequestering 
the latter from the Th2 cytokine locus (Hwang et al., 2005). Consistent with this, a recent 
study concluded that the principal function of T-bet in developing Th1 cells is to 
negatively regulate GATA-3 rather than positively regulate the ifn-γ gene (Usui et al., 
2006a). GATA-3, in contrast, appears to suppress Th1 development by down-regulating 
STAT4 and not through effects on IL-12Rβ2 or T-bet (Usui et al., 2003). 
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1.7 Rationale and aims of study 
Despite extensive studies pointing to a crucial role for ICOS in cellular and 
humoral immunity, little is known about the intracellular mechanisms underlying the 
regulation of ICOS expression in T cells, especially CD4+ T (Th) cells which play a 
crucial role in humoral immune responses. It is envisaged that the ability to enhance 
ICOS expression at the appropriate time of an ongoing host response could increase its 
effectiveness against pathogens. Conversely, the ability to down-regulate ICOS 
expression could modulate the rejection of organ and tissue transplantation and alleviate 
the severity of autoimmune diseases. Hence, in the first part of the ensuing results, we 
elucidate the signalling pathways originating from TCR and CD28 co-engagement that 
regulate ICOS induction as well as delineate the cis-acting regulatory region and trans-
acting transcription factors governing ICOS transcription during the initial 48 h of Th cell 
activation. We found that the Fyn-calcineurin-NFATc2 and MAPK/ERK kinase (MEK)2-
ERK1/2 signalling pathways operate independently but converge on the icos promoter to 
induce ICOS transcription. Moreover, we identified an ERK-sensitive site on the icos 
proximal promoter which is critical for TCR and CD28-mediated regulation of the mouse 
icos gene. 
Following ICOS induction by TCR and CD28 co-signalling which dominate 
during the early phase of Th cell activation, how ICOS expression is controlled during 
the subsequent phase of Th cell differentiation forms the subject of the second part of the 
findings. Although the role of ICOS in the overall differentiation program of Th cells in 
vivo remains controversial, its specific contribution to the production of Th2 cytokines 
and preferential expression in Th2 cells as described before led us to hypothesise that the 
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cytokine networks and downstream signalling molecules driving Th lineage commitment 
may influence ICOS expression in developing Th1 and Th2 cell subsets, in a manner 
commensurate with the differential levels of ICOS found in these subsets. We present 
evidence for the lineage-selective transcription factors T-bet and GATA-3, in cooperation 
with the more broadly expressed NFATc2 and ERK, to regulate ICOS transcription in a 
temporally dynamic and Th-specific fashion. These data, together with earlier work 
demonstrating an important role for ICOS in the transcriptional regulation of Th2 
differentiation (Nurieva et al., 2003a), argue for a bidirectional cross-talk between the 
transcriptional machinery mediating Th differentiation and the expression of a single 
costimulatory gene, Icos. 
Last but not least, we asked if the icos transcript is regulated at the post-
transcriptional level. Our investigations show that a novel RING-type E3 ubiquitin ligase, 
roquin, plays an important role in mediating the decay of ICOS mRNA via mechanisms 









MATERIALS AND METHODS 
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2.1 Mouse strains 
WT C57BL/6 mice were obtained from the Singapore Biological Resource Centre. The 
generation of Tbx21-/- (T-bet-deficient) and B6.129S7-Fyntm1Sor/J (Fyn-/-) mice were 
previously described (Finotto et al., 2002; Stein et al., 1992) and they were purchased 
from the Jackson Laboratories (Bar Harbor, ME). All mice were bred and maintained in 
accordance with Institutional Animal Care and Use Committee (IACUC) regulations and 
used between 8 – 12 weeks of age. 
 
2.2 T cell lines 
 
2.2.1 Murine EL4 T cell line 
This cell line was maintained in complete RPMI 1640 medium supplemented with 10% 
fetal calf serum (FCS) (HyClone, Logan, UT), L-glutamine (2 mM), penicillin (50 
mg/ml), streptomycin (50 mg/ml), HEPES (100 mM) and β-mercaptoethanol (55 μM). 
 
2.2.2 AE.7 Th1 and CDC35 Th2 cell clones 
The AE7 Th1 cell and CDC35 Th2 cell clones were kind gifts from Dr. I-Cheng Ho 
(Harvard Medical School, Brigham and Women’s Hospital, Boston, MA) and cultured 
according to conditions described previously (Hecht et al., 1983; Tony et al., 1985) with 
some modification. Briefly, antigen presenting cells (APCs which were splenocytes) were 
first isolated from Balb/c and AKR/J mice, treated with 50 μg/ml of mitomycin C 
(Sigma, MO) at 37°C for 45 min to mitotically arrest them and then washed with medium 
at least 3 times to eliminate traces of mitomycin C. 1 − 2 × 106 resting AE7 Th1 cells 
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were incubated with 1 × 107 growth-arrested syngeneic AKR/J splenocytes (presenting I-
Ek MHC) and 5 μM of pigeon cytochrome C in 8 ml of complete RPMI 1640 medium, 
supplemented with 10% FCS (HyClone, Logan, UT), L-glutamine (2 mM), penicillin (50 
mg/ml), streptomycin (50 mg/ml), HEPES (100 mM), Na pyruvate (1 mM), non-essential 
amino acids (100 μM) and β-mercaptoethanol (55 μM) for 48 h in a 6-well plate. The cell 
culture was then expanded in a ratio of 1:5 into 10% rat concanavalin A (con A) 
conditional medium and thereafter further expanded every 3 to 4 days. The AE7 cells 
were restimulated with antigen every 2 weeks when necessary. The conditional medium 
is α-methylmannoside (Sigma, MO)-containing supernatant from Lewis rat spleen cells 
that had been stimulated with 2.5 μg/ml of concanavalin A for 48 h and added at 10% to 
the complete medium described above as a source of lymphokines. CDC35 Th2 cells 
were cultured in similar fashion except with Balb/c splenocytes (presenting I-Ad MHC) in 
the presence of 100 μg/ml of rabbit γ-globulin. 
 
2.3 Chemical inhibitors 
Pharmacological inhibitors FK506 (10 μM), CsA (low dose: 5 ng/ml; high dose: 50 
ng/ml), both of which inhibit calcineurin, wortmannin (WM) (100 nM), which inhibits 
phosphatidylinositol-3-kinase (PI-3K), and rapamycin (RAPA) (10 nM), which inhibits 
mammalian target of rapamycin (mTOR), were obtained from Sigma-Aldrich (St Louis, 
MO). PP2 (5 μM), a broad Src family kinase inhibitor, damnacanthal (100 nM), which 
specifically inhibits Lck, piceatannol (50 μM), a Syk family kinase inhibitor, SB203580 
(10 μM), which inhibits p38 MAPK, JNK inhibitor I (5 μM) and NF-κB competitor 
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peptide SN50 (10 μM) were purchased from Calbiochem (San Diego, CA). U0126 
(50 μM) was obtained from Cell Signalling Technology (Beverly, MA). 
 
2.4 Primary murine CD4+ T cells 
2.4.1 CD4+ T cell purification 
Single cell suspensions were prepared from the peripheral lymph nodes and spleens of 
WT, Tbx21-/- and Fyn-/- mice and treated with red blood cell lysis solution (0.15 M 
NH4Cl and 0.1 mM Na2EDTA in PBS) for 5 min at 4°C to eliminate erythrocytes. CD4+ 
T cells were positively isolated using anti-CD4 antibody (mAb)–coupled magnetic cell-
sorting (MACS) microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) to more 
than 95% purity (as analysed by flow cytometric staining with anti-CD4 and anti-CD8 
Abs, data not shown). 
 
2.4.2 CD4+ T cell activation 
Purified CD4+ T cells (5 × 105) were either untreated or seeded into 24-well tissue 
culture plates pre-coated for 2 h at 37°C with 1 μg/ml anti-CD3 and 4 μg/ml soluble anti-
CD28 mAbs. In some experiments, CD4+ T cells were incubated with chemical 
inhibitors 1 h prior to activation. 
 
2.4.3 CD4+ T cell differentiation in vitro 
Purified CD4+ T cells (2 × 106/ml) were stimulated with 1 μg/ml plate-bound anti-CD3 
and 4 μg/ml soluble anti-CD28 mAbs in 48-well tissue culture plates under Th0 (3 μg/ml 
anti–IL-12 plus 5 μg/ml anti–IFN-γ plus 10 μg/ml anti–IL-4), Th1-skewing (5 ng/ml 
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IL-12 plus 10 μg/ml anti–IL-4) or Th2-skewing (10 ng/ml IL-4 plus 3 μg/ml anti–IL-12 
plus 5 μg/ml anti–IFN-γ) conditions. 100 U/ml recombinant mouse IL-2 was added after 
24 h, and the cells were expanded in complete medium to culture Th cell lines as 
described above but containing IL-2 for 2 or 8 d. Recombinant mouse IL-2, IL-4 and 
IL-12 were purchased from PeproTech Inc. (Rocky Hill, NJ). NA/LE-grade anti-CD3 
(145-2C11), anti-CD28 (37.51), anti–IL-12 (C17.8), anti–IFN-γ (XMG1.2) and anti–IL-4 
(11B11) were obtained from BD Biosciences. 
 
2.4.4 Retroviral Constructs and Retroviral Transduction of CD4+ T cells activated 
by anti-CD3 and anti-CD28 
The bicistronic vectors green fluorescent protein(GFP)-RV and T-bet-RV, kind gifts of 
Dr. Laurie H. Glimcher (Harvard School of Public Health, Boston, MA), were described 
previously (Szabo et al., 2000). The Phoenix-Eco packaging cell line was obtained from 
Dr. Gary P. Nolan (Hofmann et al., 1996). The GFP-RV vector was constructed by 
inserting the encephalomyocarditis virus internal ribosomal entry sequence (IRES) and 
the GFP allele into the MSCV2.2 retroviral vector (Ouyang et al., 1998). Full-length 
murine GATA-3 cDNA was generated by PCR using pcDNAHis-GATA-3 as template. 
The primers used were 5′-GAA GAT CTT CGG AAT TCG ACA TGG AGG TGA CTG 
CG-3′ and 5′-CCG CTC GAG CGG GCT CTA GAC TAA CCC ATG GCG GTG A-3′. 
The PCR product, digested with both BglII and XhoI, was then ligated to similarly 
digested GFP-RV vector to generate GATA-3-RV. The vectors express two cDNAs, one 
encoding T-bet or GATA-3 and the other GFP, and simultaneously use an IRES to 
initiate translation of each mRNA separately. Transfection of the packaging cell line and 
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retroviral transduction of primary CD4+ T cells were described elsewhere (Ouyang et al., 
1998) and performed with little modification. CD4+ T cells activated with plate-bound 
anti-CD3 and soluble anti-CD28 were infected after ∼24 h using a 1:2 volume of viral 
supernatant and polybrene (Sigma, MO) at 8 μg/ml, centrifuged at 1800 rpm for 45 min 
at room temperature, and incubated at 37°C for between 12 and 24 h before being 
replaced with media containing IL-2 and expanded for an additional 48 h after primary 
activation. Flow cytometric analysis of surface CD4 and ICOS on GFP-positive cells was 
then performed (see below for details on how flow cytometry was performed). To isolate 
RNA or extract protein from cells, they were first sorted (to greater than 98% being GFP-
positive, data not shown) on a FACS-Vantage Flow Cytometer/Cell Sorter (Becton 
Dickinson, Mountain View, CA). 
 
2.5 Intracellular cytokine staining (ICS) and flow cytometric analyses 
Naïve, activated, retrovirally transduced or polarised Th cells were stained with optimal 
amounts of anti-CD4 FITC and anti-ICOS PE Abs. CD4+ T cells stimulated with anti-
CD3 and anti-CD28 and retrovirally infected were stained with anti-CD4 biotin and anti-
ICOS PE Abs. PE-Cy5-conjugated streptavidin was used in a secondary step to reveal 
biotinylated CD4 staining. ICS of Th cells was performed using the BD 
Cytofix/Cytoperm™ Plus Fixation/Permeabilization Solution Kit with BD GolgiStop™ 
according to manufacturer’s instructions. Th cells (∼ 2 × 106) were first treated with 4 μl 
of BD GolgiStop™ Protein Transport Inhibitor (containing monensin) for every 6 ml of 
culture media and PMA (50 ng/ml) and ionomycin (0.5 μg/ml) for 6 h at 37°C. Cells 
were then harvested and stained with anti-CD4 biotin followed by PE-Cy5-conjugated 
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streptavidin. After 2 washes with staining buffer (3% FCS, 0.1% NaN3 in PBS), cells 
were fixed and permeabilised for 20 min at 4°C. Cells were then washed twice with 1 × 
BD Perm/Wash™ buffer and thoroughly resuspended in 50 μl of Perm/Wash™ buffer 
containing pre-determined optimal concentrations of anti-IFN-γ FITC and anti-IL-4 PE or 
their corresponding isotype controls. After incubation for 30 min at 4°C in the dark, cells 
were again washed with Perm/Wash™ buffer and resuspended in about 300 − 400 μl of 
staining buffer. Cells were stained with fluorochrome-conjugated anti-CD4 and anti-
ICOS Abs and analysed on a FACScan flow cytometer using CellQuest software (Becton 
Dickinson, Mountain View, CA). The following Abs were purchased from BD 
Pharmingen (San Diego, CA): NA/LE-grade anti-CD3 (145-2C11) and anti-CD28 
(37.51) Abs for cell stimulation, FITC and biotin-conjugated anti-CD4 (GK1.5), anti-
CD8 (53-6.7), PE- and biotin-conjugated anti-ICOS (7E.17G9), PE-Cy5-conjugated 
streptavidin, anti-IFN-γ FITC (XMG1.2) and anti-IL-4 PE (11B11). 
 
2.6 RNA isolation and real-time RT-PCR analyses 
Total RNA was isolated using TRIzol and treated with DNase I (Invitrogen Life 
Technologies, Carlsbad, CA) to avoid DNA contamination; cDNA was prepared using 
SuperScript III Reverse Transcriptase (Invitrogen) with oligo(dT)12-18 as primer. Primers 
used for real-time PCR are: ICOS, 5′-TGA CCC ACC TCC TTT TCA AG-3′ and 5′-TTA 
GGG TCA TGC ACA CTG GA-3′; β-actin, 5′-GAT CTG GCA CCA CAC CTT CT-3′ 
and 5′-ACC AGA GGC ATA CAG GGA CA-3′. Each reaction (95°C, 2 min; 95°C, 10 s; 
60°C, 30 s; 72°C, 30 s, 40 cycles) was performed in a Mx3000P QPCR System 
(Stratagene) using QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA) or the 
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SYBR Green PCR Kit (Invitrogen). All experiments were done at least twice, and mRNA 
levels of ICOS were normalised to those of the housekeeping gene, β-actin. The levels of 
mRNA in activated, retrovirally transduced or differentiated cells were expressed as a 
fold change relative to levels in naïve cells. Statistical analysis (unpaired two-tailed 
Student’s t test) was performed with PRISM software (GraphPad Software, San Diego, 
CA). 
 
2.7 Western blotting 
Cells (2 – 5 × 106) were lysed on ice for 15 min in a buffer containing 1% (v/v) Nonidet 
P-40, 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 0.2 mM Na3VO4, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 10 μg/ml aprotinin, and the debris was 
removed by centrifugation at 13,000 rpm for 12 min at 4°C. Following determination of 
protein concentrations of lysates using Bradford assay (Bio-Rad Laboratories, Hercules, 
CA), they were then loaded in equal amounts and electrophoresced in a 7–10% SDS-
PAGE, electroblotted onto polyvinylidene difluoride (PVDF) membrane, and probed 
with Abs that recognise specific proteins. Protein bands were visualised using horseradish 
peroxidase-coupled Abs and the enhanced chemiluminescence detection system 
(SuperSignal West Pico Chemiluminescent Substrate System from Pierce Biotechnology, 
Rockford, IL). Abs against T-bet (4B10), GATA-3 (HG3-31), phospho-ERK (E-4), 
ERK2 (C-14), NFATc2 (G1-D10), HDAC1 (H-51), TFIID (58C9) and β-actin (C-11) 
were all obtained from Santa Cruz Biotechnology. 
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2.8 Plasmid constructs 
The icos promoter, spanning −1478 and −1 relative to the first nucleotide of the mouse 
cDNA (NCBI GenBank accession number NM_017480) was amplified from C57BL/6 
mouse genomic DNA by PCR using primers carrying restriction sites for KpnI and 
HindIII, 5′-GAG CAG TCA TTG AGA GGC CAG AAG AG-3′ and 5′-CCC AAG CTT 
AGT GCT CAA AAG TGT CAG-3′, and cloned into the promoterless luciferase (luc) 
plasmid vector, pGL3-Basic (pGL3B; Promega, Madison, WI) to create 
mICOSp(−1478)-Luc. 5′ deletion mutants of this promoter fragment were either 
generated after suitable restriction enzyme digestion and religated into pGL3B or 
subcloned by nested PCR to create mICOSp(−900)-Luc, mICOSp(−599)-Luc, 
mICOSp(−471)-Luc, mICOSp(−288)-Luc, mICOSp(−147)-Luc, mICOSp(−109)-Luc and 
mICOSp(−52)-Luc. A 259-bp fragment of the icos 3′UTR (NCBI GenBankTM accession 
no. AK030827) containing putative NFATc2 and GATA-3 binding sites was generated 
by PCR from C57BL/6 mouse genomic DNA using the primers 5′-GAT GTT CCC ATA 
TTC TCC-3′ and 5′-CCA GGA GAA TGT TTG CCC-3′ and cloned into the BamHI / 
SalI sites of mICOSp(-52)−Luc to generate a luc reporter vector driven by a minimal 
52-bp icos promoter containing a 259-bp icos 3′UTR fragment downstream of the luc 
gene. A 3-bp region CTT between 142 and 144 bp within mICOSp(−288)-Luc was 
replaced by AGA using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) to 
create mICOSp(−288)-ERK-mut-Luc. The same protocol was used to replace a 2-bp 
section CC between 231 and 232 bp with AA in mICOS(−288)-Luc to generate 
mICOSp(−288)-NFAT-mut-Luc. The plasmids encoding roquin WT and roquin M199R, 
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kind gifts of Dr. Carola G. Vinuesa (John Curtin School of Medical Research, The 
Australian National University, Canberra) were described previously (Vinuesa et al., 
2005a). Briefly, the coding sequence of roquin mRNA was amplified using PCR from 
C57BL/6 spleen cDNA, A-tailed with Taq DNA polymerase and cloned in-frame with 
GFP in the pCDNA3.1 CT-GFP TOPO TA fusion vector, to generate roquin WT vector. 
The Met (amino acid position 199) → Arg substitution was introduced by site-directed 
mutagenesis to yield roquin M199R, which carries a single base (T → G) mutation in a 
novel ROQ domain. The pUSEamp vector expressing a constitutively active form of 
MEK2 (S222D/S226D double mutant) was purchased from Upstate Biotechnology. The 
pBJ5 and pBJ5-NFATc1 vectors were generously provided by Dr Neil A. Clipstone 
(Northwestern University, Chicago, IL). The pBJ5-NFATc2 (pSH210) and 
pBJ5-NFATc3 (pSH250A) vectors were kind gifts of Dr Gerald R. Crabtree (Stanford 
University, Stanford, CA). Sequences of all DNA constructs were confirmed by 
automated sequence analyses. 
 
2.9 Transient transfections in EL4 cells 
For luc assays, 0.98 μg of the luc reporter plasmid and 0.02 μg of pRL-TK (Renilla) 
plasmid (50:1 ratio) (total amount of DNA = 1 μg) were premixed in OPTI-MEM I 
reduced serum medium (Invitrogen) and transiently transfected with Lipofectamine 2000 
reagent (Invitrogen) in triplicate into EL4 cells seeded in 24-well flat-bottom plates at 
1 × 106 cells/ml in 0.5 ml of RPMI 1640 medium without antibiotics following 
manufacturer’s recommendations. For example, to transfect 1 μg of DNA, 3 μl of 
Lipofectamine 2000 was first mixed with 47 μl of OPTI-MEM I for 5 min at room 
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temperature. Concurrently, 1 μg of DNA was also mixed with the same volume of OPTI-
MEM I and the two mixtures were incubated together after 5 min for a further 20 min to 
allow liposome-DNA complex formation. This total mixture was subsequently added to 
each well of plated cells, which were incubated at 37°C in 5% CO2 for 4 h before 
stimulation with 10 ng/ml PMA and 0.5 μg/ml ionomycin. Cells were cultured for 
another 14 to 16 h before being harvested by centrifugation. 
 
2.10 Luc reporter assays 
Following overnight culture as described in the previous section, cell pellets were 
solubilised in 1 × passive lysis buffer (Promega) and incubated on a Spiramix roller 
mixer for 15 min at room temperature. 20 μl of cell lysate was assayed for both fire-fly 
and Renilla luc activities using the Dual-Luciferase Reporter Assay System (Promega), 
and relative light units (RLU) were measured in a TD-20/20 single-tube luminometer 
(Turner BioSystems, Sunnyvale, CA). RLU from the fire-fly luciferase (luc) was 
normalised for transfection efficiency to the Renilla luc RLU in each lysate (normalised 
RLU = RLUfire-fly luc / RLURenilla luc). For icos promoter or 3′UTR analysis, the activity of a 
reporter construct following stimulation was calculated as: Reporter Activity = 
normalised RLUstimulated / normalised RLUunstimulated. For effect of over-expressed proteins 
on promoter or 3′UTR activities, the fold induction was calculated as: Fold Induction = 
normalised RLUprotein expressing vector, unstimulated or stimulated / normalised RLUnull vector, unstimulated. 
33 
2.11 siRNA knockdown of T-bet and GATA-3 respectively in AE7 and CDC35 
cells 
AE7 cells were transfected using Lipofectamine 2000 with 100 nM of Tbx21 siRNA 
ID#181595 (which targets exon 3 and designated T-bet siRNA #1), 100 nM of siRNA ID 
#181596 (which targets exon 6 and designated T-bet siRNA #2) or 100 nM of Silencer® 
GFP (eGFP) siRNA (cat #AM4626) as negative control. CDC35 cells, on the other hand, 
were transfected with 1 μM of GATA-3 siRNA ID #61725 (which targets exon 2 and 
designated GATA-3 siRNA #1), 1 μM of ID #61780 (which targets exon 5 and 
designated GATA-3 siRNA #2) or 100 nM of GFP siRNA as negative control. Both T-
bet siRNAs were pre-designed using Tbx21 gene sequence information derived from 
GenBank acc. no. NM019507 while those for GATA-3 were designed using GenBank 
acc. no. NM008091 as reference. All siRNA duplex oligonucleotides with catalog IDs as 
indicated above were purchased from Ambion, Inc., Applied Biosystems, Austin, TX. 
Following transfection, cells were rested for 24 h before additional transfection with 
appropriate luc reporter vectors and stimulation for luc assays or stimulation alone for 
ChIP assays. 
 
2.12 Chromatin immunoprecipitation (ChIP) 
ChIP was performed according to the manufacturer’s protocol (Upstate Biotechnology, 
Lake Placid, NY) with some modifications. Naïve, anti-CD3/CD28-activated CD4+ T 
and differentiating Th cells (2 – 5 × 106) stimulated or not by PMA and ionomycin for 6 h 
were cross-linked with formaldehyde at a final concentration of 1% for 10 min at 37°C, 
washed with ice-cold PBS containing 1 mM PMSF, harvested and lysed in 10% SDS 
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buffer. DNA was sheared by ultrasonication using a High Intensity Ultrasonic Processor 
(Heat Systems) for 8 × 12 s pulses at 30% amplitude. Lysates were cleared by 
centrifugation, diluted in ChIP dilution buffer and pre-cleared using salmon sperm 
DNA/protein A-agarose and a sample of input DNA was collected at this point. Protein-
DNA complexes were immunoprecipitated with 6 μg of an Ab against the protein of 
interest or isotype-matched control overnight at 4°C. Ab-protein-DNA complexes were 
then captured using salmon sperm DNA/protein A-agarose for 1 h at 4°C. After washing 
beads with low and high salt, LiCl and TE buffers, the protein/DNA complexes were 
eluted using 1% SDS, 0.1 M NaHCO3 buffer and disrupted by heating at 65°C for 4 h. 
DNA was then phenol/chloroform- extracted, ethanol-precipitated and subjected to PCR 
using various primers (15 s at 94°C; 30 s at 60°C and 1 min at 72°C, completed by 10 
min at 72°C, 28 − 30 cycles). The following primers were used: a pair spanning −288 to 
TSS of icos promoter (ICOS P): sense 5′-CCG CTC GAG CAT GCA TGC ATC CAT C-
3′; antisense 5′-CCC AAG CTT AGT GCT CAA AAG TGT CAG-3′ (288-bp product); a 
pair spanning a 259-bp stretch of icos 3′UTR (ICOS E), 5′-GAT GTT CCC ATA TTC 
TCC-3′ and 5′-CCA GGA GAA TGT TTG CCC-3′ (259-bp product). The antibodies 
used were anti-NFATc2 (G1-D10) and mouse IgG2a isotype control, anti-T-bet (4B10) 
and mouse IgG1 isotype control, and anti-GATA-3 (HG3-31) and mouse IgG1 isotype 
control from Santa Cruz. Anti-H3K4me3 Ab was from Upstate Biotechnology, Lake 
Placid, NY and its control is rabbit anti-mouse serum. PCR products were finally 
separated on 2% agarose gels. 
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2.13 Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction 
Reagents Kit (Pierce Biotechnology, Rockford, IL) with minor adjustments. Cells 
(10 × 106) were untreated or stimulated for 16 h and washed in PBS at 4°C. Nuclear 
extracts were prepared by hypotonic lysis and high salt extraction, and subsequently 
cleared of insoluble material by centrifugation at 13,000 rpm for 5 min at 4 °C before 
being concentrated with a microcon-3 column (Millipore Corp., Billerica, MA). The 
extracts were stored at −80°C prior to use, and protein content measured using Bradford 
assay (Bio-Rad Laboratories). For gel shift assays, double-stranded oligonucleotide 
probes were end-labeled with [γ-32P]ATP using T4 polynucleotide kinase (New England 
Biolabs, Beverly, MA). Labeled probes were purified using ProbeQuant G-50 micro 
columns (Amersham Pharmacia Biotech, Piscataway, NJ). Binding reactions were 
conducted at room temperature for 20 min in a 20 μl total volume containing 0.5 ng of 
labeled probe, 5 μg of nuclear extract, 1 μg of poly(dI⋅dC) (Amersham Pharmacia 
Biotech) and gel shift buffer (12 mM HEPES, pH 7.9, 4 mM Tris-HCl, pH 7.9, 60 mM 
KCl, 5 mM MgCl2, 5 mM dithiothreitol (DTT) and 12.5% glycerol). For competition 
assays, competing oligonucleotides were preincubated with the reaction mix at room 
temperature for 15 min before the addition of radiolabeled probe. Binding reactions were 
size-fractionated using a 5% non-denaturing PAGE in 0.5 × TBE and electrophoresed at 
120 V for 4 h at room temperature. The gel was subsequently transferred onto 3MM 
chromatography paper, dried and exposed to autoradiographic film for 1 to 3 days at 
−80°C. The probe sequences were: p154_105, 5′-TCA CCG GGT ACT TGC CAT GCA 
GGA GGC GCT GTG ATA GCT CTC CAA GTA GA-3′ and p154_130, 5′-TCA CCG 
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GGT ACT TGC CAT GCA GGA G-3′. Competitor sequences were: p154_105, as above; 
p154_130, as above; p129_105, 5′-GCG CTG TGA TAG CTC TCC AAG TAG A-3′; 
p154_130_mut, 5′-TCA CCG GGT AAG A1GC CAT GCA GGA G-3′; NF-κB 
consensus, 5′-AGT TGA GGG GAC TTT CCC AGG C-3′; NFATc consensus, 5′-CGC 
CCA AAG AGG AAA ATT TGT TTC ATA-3′; Ets-1 consensus, 5′-GAT CTC GAG 
CAG GAA GTT CGA-3′; Elk-1 consensus, 5′-GGG CTG CTT GAG GAA GTA TAA 
GAA T-3′; Elf-1, 5′-CTT GGG GGC AGG ACT TCC TGT TTC T-3′ (Sarafova and Siu, 
1999); CP2/LSF consensus, 5′-GTC TGA TTT CAC AGG AA-3′ (Casolaro et al., 2000); 
Sp1 consensus, 5′-ATT CGA TCG GGG CGG GGC GAG C-3′; AP1 consensus, 5′-CGC 
TTG ATG ACT CAG CCG GAA-3′. 
                                                          












3.1 Induction of ICOS expression by TCR and CD28 co-engagment 
3.1.1 Induction of ICOS by TCR and CD28 is subject to transcriptional control 
ICOS expression is induced upon T cell activation and, in particular, in response 
to TCR and CD28 co-engagement (McAdam et al., 2000). To examine in detail the 
kinetics of ICOS induction, we first determined the level of ICOS cell surface expression 
and correlated that with the induction of ICOS mRNA in murine primary CD4+ T cells 
stimulated with anti-CD3 and anti-CD28 Abs, which engaged the TCR and CD28 
receptor respectively (henceforth designated as TCR/CD28). As shown in Figure 3.1A, 
an increase in cell surface expression of ICOS could be detected as early as 6 h of T cell 
activation using a fluorochrome-conjugated anti-ICOS antibody in flow cytometry 
analysis, and the expression level seemed to peak at 40 h of T cell stimulation. At the 
transcriptional level, an increase in ICOS mRNA could be detected via real-time RT-PCR 
as early as 3 h after TCR/CD28 stimulation and the mRNA level appeared to peak and 
plateau from 6 to 18 h before declining (Figure 3.1B). Thus, it was evident from the 
temporal increase in mRNA and cell surface protein expression that ICOS was subjected 




Figure 3.1 ICOS expression is induced at the transcriptional level upon T cell 
activation. 
 
A, Purified murine primary CD4+ T cells were stimulated with plate-bound anti-CD3 
(1 μg/ml) and soluble anti-CD28 (4 μg/ml) antibodies for various times as indicated and 
analysed for cell surface expression of ICOS by flow cytometry. ICOS expression on 
stimulated cells (thick line) is compared with that of unstimulated cells at 0 hr (thin line). 
Data shown are representative of 2 independent experiments. B, ICOS mRNA levels in T 
cells activated for various times were analysed by quantitative real-time RT-PCR. Data 
shown had been normalised to those from unstimulated cells at 0 hr and were expressed 
as mean values ± SEM of at least 2 independent experiments. 
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3.1.2 ICOS expression is regulated by distinct pathways downstream of TCR and 
CD28 signalling 
Since TCR/CD28 stimulation could lead to an increase in ICOS mRNA and cell 
surface protein expression, we were interested to characterise the signalling pathways that 
regulate ICOS induction. To accomplish this, we first utilised a range of chemical 
inhibitors to block intracellular signalling pathways known to be activated by TCR/CD28 
engagement in primary CD4+ T cells and assessed their effects on the induction of cell 
surface ICOS expression (Figure 3.2A). Our data shows that FK506 (tacrolimus), which 
is known to inhibit calcineurin, substantially diminished cell surface expression of ICOS 
on activated T cells, thus suggesting a possible role for this pathway in ICOS induction 
(Figure 3.2A, left panel). This was consistent with a previous study that showed an 
inhibitory effect of CsA, which also deactivates calcineurin, on ICOS induction in human 
CD4+ T cells (Beier et al., 2000). Furthermore, as calcineurin is Ca2+-sensitive, blocking 
Ca2+ elevation with EGTA, also mitigated the induction of ICOS (data not shown). To 
determine whether the reduction in cell surface expression of ICOS on activated T cells 
by FK506 treatment was in part a consequence of reduced transcription, we assayed the 
amount of ICOS mRNA in FK506- and CsA-treated TCR/CD28-stimulated CD4+ T 
cells. Indeed, as seen in Figure 3.2C, pre-treatment of these activated cells with FK506 
and CsA both reduced the amount of ICOS mRNA up-regulation compared to untreated 
cells, indicating that this signalling pathway probably acts at the level of ICOS 
transcription. In addition, we showed that PP2 but not piceatannol also attenuated 
TCR/CD28-induced ICOS induction, hence implicating Src rather than spleen tyrosine 
kinase (Syk) family of protein tyrosine kinases in regulating ICOS expression (Figure 
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3.2A, left panel). Again, the regulation of ICOS by the Src family kinases appeared to be 
at the transcriptional level as PP2-treated TCR/CD28-activated CD4+ T cells had reduced 
levels of ICOS mRNA compared to control cells (Figure 3.2B). To ascertain which of the 
Src kinases were involved (Fyn and Lck being the most highly expressed in T cells), we 
treated cells with damnacanthal, a highly potent and selective inhibitor of Lck activity 
(Faltynek et al., 1995). ICOS induction at both the cell surface protein and mRNA 
expression levels were unaltered by damnacanthal treatment, thus implicating Fyn but not 
Lck as the primary tyrosine kinase involved (Figure 3.2A, left panel and B). Although we 
could not rule out a possible role for Src kinase, our analysis of Fyn-/- CD4+ T cells 
indicated that Fyn likely plays a major role in inducing ICOS expression as these cells 
expressed reduced levels of cell surface ICOS protein or ICOS mRNA compared to Fyn-
sufficient cells upon TCR/CD28 stimulation (respectively Figure 3.2C and D). 
TCR/CD28 engagement is also known to activate the various MAPKs (Rudd and 
Schneider, 2003). We found that extracellular signal-regulated protein kinase (ERK), but 
not JNK (c-Jun NH2-terminal kinase) or p38 MAPK, played a critical role in ICOS 
induction. ICOS induction was virtually abrogated when TCR/CD28-activated CD4+ T 
cells were pre-treated with the ERK inhibitor, U0126, but not with the JNK inhibitor (L-
form) or p38 inhibitor, SB203580 (Figure 3.2A, middle panel). This inhibition appeared 
to act also at the transcriptional level, similar to that mediated by CsA and PP2 (Figure 
3.2B). 
Despite a number of studies emphasizing the importance of PI-3K in CD28 
signalling leading to cell activation, proliferation and survival (Pages et al., 1994; Prasad 
et al., 1994; Stein et al., 1994), ICOS induction did not seem to be dependent on PI-3K or 
42 
mTOR pathways because treatment of cells with wortmannin (WM) or rapamycin 
(RAPA) respectively, did not affect TCR/CD28-mediated ICOS up-regulation (Figure 
3.2A, right panel). We also did not observe any effect of SN-50 inhibitor peptide on 
ICOS induction, thus indicating a negligible or redundant role for NF-κB in TCR/CD28-
mediated ICOS induction. 
As a control to ensure that the dampening of ICOS induction by some of the 
chemical inhibitors examined above was not due to their effect on the surface expression 
of CD3 and/or CD28 molecules leading to diminution of ICOS induction, we treated 
CD4+ T cells with these inhibitors for 16 h and found that the cell surface expression of 
CD3 (data not shown) and that of CD28 were unaffected by these inhibitors (Figure 
3.2F). 
Finally, we also addressed the feasibility of using the mouse EL4 T cell line as a 
model for subsequent study of ICOS regulation. Although there was already a high level 
of basal ICOS transcript in EL4 cells, the level of ICOS mRNA in these cells could be 
further elevated upon TCR/CD28 or PMA and ionomycin (henceforth designated as P/I) 
treatment (Figure 3.2E and data not shown). Importantly, like in primary CD4+ T cells, 
TCR/CD28-induced ICOS mRNA induction in EL4 cells could also be blocked by PP2, 
U0126 and CsA. Thus, taken together, our results using both murine primary CD4+ T 
cells and EL4 T cells indicate that Fyn, calcineurin and ERK are the primary signalling 




 Figure 3.2 ICOS induction by TCR and CD28 engagement is regulated by 
distinct downstream signalling pathways. 
 
A, ICOS induction on activated CD4+ T cells pre-treated with various chemical 
inhibitors. Purified CD4+ T cells were pre-treated with various inhibitors for 1 hr and 
stimulated as in Figure 3.1 for 40 − 48 h prior to examination of surface ICOS expression 
via flow cytometry (thick and thin lines are as depicted in Figure 3.1). Data shown are 
representative of 2 independent experiments. B, Measurement of ICOS mRNA levels in 
activated CD4+ T cells pre-treated with inhibitors. Cells were stimulated as above and 
harvested 6 h later to assess ICOS mRNA levels by real-time RT-PCR. Data were 
normalised to those from unstimulated cells and shown as mean ± SEM of at least 2 
independent experiments. C and D, Purified CD4+ T cells from Fyn+/+ and Fyn-/- mice 
were stimulated and harvested as in Figure 3.1. Cell surface ICOS expression and ICOS 
mRNA levels were assessed by flow cytometry and real-time RT-PCR respectively. Data 
shown are mean values ± SEM of 2 independent experiments. E, Murine EL4 thymoma 
cells were treated as in A and harvested after 14 − 16 h, and ICOS mRNA levels were 
quantified by real-time RT-PCR. F, CD28 expression on naive CD4+ T cells pre-treated 
with various chemical inhibitors. T cells were treated as in A and harvested after 
14 − 16 h prior to assessment of surface CD28 expression via flow cytometry (thick and 
thin lines are as depicted in Figure 3.1). * indicates p < 0.05; ** p < 0.01; *** p < 0.001. 
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3.1.3 Fyn induces ICOS transcription in part through NFATc2 independently of 
ERK 
Since the above study with U0126 implicated ERK in TCR/CD28-mediated ICOS 
induction, we expressed a constitutively active form of MEK2 (caMEK2), which is the 
upstream kinase of ERK, in EL4 cells to determine if hyperactivation of ERK would 
result in enhanced ICOS induction. As shown in Fig. 3.3A, the expression of increasing 
amounts of caMEK2 resulted in a dosage-dependent induction of ICOS mRNA levels. 
This result, together with our previous data using U0126, unambiguously established a 
role for ERK in ICOS induction. 
As we demonstrated earlier that the signalling pathways leading to TCR/CD28-
mediated ICOS induction were sensitive to CsA and FK506 (Figure 3.2A, B and E), we 
hypothesised that NFAT proteins could be involved in TCR/CD28-mediated ICOS 
induction. Three NFAT family members are known to be expressed in T cells, namely, 
NFATc1, NFATc2 and NFATc3 (Macian, 2005). As shown in Figure 3.3B, over-
expression of NFATc2 in P/I-treated EL4 cells led to a significant increase in ICOS 
mRNA levels whereas the levels of ICOS mRNA induction were modest or negligible in 
P/I-treated EL4 cells respectively over-expressing NFATc1 or NFATc3. Thus, NFATc2 
is involved in TCR/CD28-induced ICOS mRNA up-regulation. 
The studies so far had indicated that Fyn, ERK, calcineurin and NFATc2 were 
involved in TCR/CD28-mediated ICOS induction. However, within the TCR/CD28 
signal transduction hierarchy, the participation of Fyn and ERK is proximal with respect 
to the downstream transcription factor NFATc2. To determine if Fyn- or ERK-mediated 
ICOS induction occurs in part via NFATc2, we examined the effect of NFATc2 over-
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expression in TCR/CD28-stimulated EL4 cells pre-treated with PP2 or U0126 (Figure 
3.3C). As expected, PP2 or U0126 treatment inhibited ICOS induction in TCR/CD28-
stimulated EL4 cells. Interestingly, NFATc2 over-expression could overcome the 
dampening of ICOS induction in PP2-treated but not U0126-treated TCR/CD28-activated 
EL4 cells in a dose-dependent manner, suggesting that NFATc2 is probably downstream 





















































Figure 3.3 Induction of ICOS 
transcription by ectopic expression of 
MEK2 and NFATc2. 
 
A, EL4 cells were transfected with a null 
vector or increasing amounts of 
constitutively active MEK2 (caMEK2) 
and the amount of ICOS mRNA was 
quantified by real-time RT-PCR; 
**p< 0.001. B, EL4 cells were 
transfected with vectors expressing 
NFATc1, NFATc2 or NFATc3, and 
either left unstimulated (white bars) or 
stimulated with PMA and ionomycin 
(black bars) and examined for ICOS 
mRNA levels via RT-PCR; ** p < 0.001. 
C, EL4 cells transfected with null vector 
(white bars) or NFATc2 vector (black 
bars) were pre-treated with U0126 or 
PP2 and stimulated with anti-CD3 and 
anti-CD28 Abs and their ICOS mRNA 
levels were assessed by real-time RT-
PCR. Data were normalised to cells 
transfected with null vector and shown as 
mean ± SEM of 2 independent 




NFATc2 resides in the cytoplasm and translocates to the nucleus upon activation 
(Rao et al., 1997). Consistent with the above finding that NFATc2 is downstream of Fyn 
but not ERK signalling, we also found that PP2 but not U0126 pre-treatment of 
TCR/CD28-stimulated EL4 cells resulted in a reduction of NFATc2 translocation into the 
nucleus compared to untreated or U0126-treated cells that were subjected to the same 
stimulus (Figure 3.4A). 
Although most studies of TCR signalling have positioned ERK downstream of 
Fyn in the TCR signalosome, our data seems to indicate that ERK acts in a signalling axis 
distinct from Fyn in regulating ICOS upon TCR/CD28 stimulation. To further clarify 
this, we examined ERK activation in the absence of Fyn signalling in EL4 cells. As 
shown in Figure 3.4B, TCR/CD28-stimulated EL4 cells, with or without PP2 pre-
treatment, was comparable. This is consistent with previous work showing the same 
between Fyn+/+ and Fyn-/- CD4+ T cells (Cannons et al., 2004). It is therefore apparent 
that Fyn does not act through ERK to initiate ICOS transcription and that ERK acts in an 
independent signalling pathway to regulate ICOS. Collectively, our data demonstrate that 







Figure 3.4 PP2 treatment affects NFATc2 nuclear translocation but not Erk 
activation. 
 
A, EL4 cells were untreated or pre-treated with PP2 or U0126 and subsequently 
stimulated with anti-CD3 and anti-CD28 Abs for 16 h. Nuclear extracts (10 μg) were 
subjected to immunoblotting with anti-NFATc2 mAb. The anti-TFIID blot serves as 
control for equal loading of extracts. B, EL4 cells were either untreated or pre-treated 
with PP2 and then stimulated for the times indicated. ERK activation was assessed by 
Western blotting using anti-phospho-ERK Ab and the anti-ERK2 blot serves as a loading 
control. 
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3.1.4 A 288-bp core promoter region of icos confers PMA and ionomycin-induced 
expression of a reporter in vitro 
To further elucidate the molecular mechanisms leading to icos promoter 
activation, we first tested a 1.48-kb KpnI−HindIII fragment 5′ of the transcription start 
site (TSS) of the mouse icos gene for evidence of promoter activity. This fragment was 
linked in the sense orientation to the promoterless luc reporter vector pGL3B to create 
mICOSp(−1478)-Luc, which was transiently co-transfected with a normalisation vector, 
pRL-Renilla into EL4 cells. Subsequently, cells were left in medium alone or stimulated 
with P/I, and after a further 14 to 16 h of incubation, harvested and evaluated for luc 
activity. P/I were used instead of anti-CD3 and anti-CD28 Abs for stimulating cells as the 
former treatment gave a larger fold increase in luc activity compared to the latter (data 
not shown). 
As seen in Figure 3.5A, the icos 5’ 1.48-kb DNA fragment conferred significant 
luc activity in stimulated EL4 cells. There was an approximately 61-fold induction in luc 
activity in cells stimulated with P/I compared to cells in medium only. As a control, 
insertion of the same promoter fragment in the antisense orientation resulted in a 
complete loss of its ability to activate the reporter construct (data not shown). Thus, the 
data indicates that the 1.48-kb region upstream of icos TSS contains significant promoter 
activity. 
To define more specifically the elements contributing to icos promoter activity, 
we generated a series of promoter mutants by truncating the 1.48-kb DNA fragment from 
the 5′ end. While the 900-bp BglII−HindIII (−900 to −1) and the 599-bp XhoI−HindIII 
(−599 to −1) fragments retained promoter activity, additional deletion of the icos 
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promoter revealed that a 288-bp fragment was the minimum region responsible for 
substantial transcriptional activating capability associated with the 1.48-kb parental 
fragment. A further 5′ truncation yielding a 147-bp fragment resulted in dramatic 
reduction of promoter activity (∼10-fold loss in luc activity) and subsequent deletions 
leading to 109-bp and 52-bp fragments led to an almost complete loss of promoter 
activity (Figure 3.5A). Hence, based on these in vitro luc reporter assays, we concluded 
that the 288 bp region upstream of the icos TSS was the minimum DNA region that 
retained significant promoter activity capable of conferring high level of induced ICOS 
transcription. 
 
3.1.5 Requirement of NFATc2 and ERK-dependent transcription factor(s) for icos 
core promoter activity 
We next asked if Fyn-NFATc2 and ERK signalling cascades could influence the 
core promoter activity of icos. To this end, we assessed the effects of CsA and U0126 
treatment on the promoter activity of the 288-bp, 147-bp and 109-bp DNA fragments of 
icos. We observed that CsA treatment reduced markedly the reporter activity of 
the 288-bp but not the 147-bp fragment following transient co-transfection of 
mICOSp(−288)-Luc, mICOSp(−147)-Luc or mICOSp(−109)-Luc and pRL-Renilla in 
EL4 cells (Figure 3.5B, left panel). In contrast, U0126 treatment virtually obliterated the 
promoter activities of both the 288-bp and 147-bp fragments, suggesting that ERK 
signalling has a very profound effect on the activation status and/or DNA binding activity 
of potential transcription factors that recognise the cis-regulatory elements within the 
147-bp region (Figure 3.5B, right panel). In addition, our data suggests that CsA-sensitive 
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transcription factors such as NFAT probably act within the region between 288 and 
147 bp upstream of icos TSS. 
To further support the findings that ERK and NFAT signalling are involved in the 
induction of ICOS transcription through specific action within the 288-bp promoter 
region, we over-expressed individually caMEK2 and NFATc2 in cells harbouring 
mICOSp(−288)-Luc. Both caMEK2 and NFATc2 could enhance the promoter activity of 
mICOSp(−288)-Luc (Figure 3.5C, left panel). Strikingly, co-transfection of both led to a 
synergistic amplification of promoter activity, suggesting the possibility of cooperation 
between the ERK-responsive transcription factors and NFATc2 in accentuating icos 
promoter activity. Thus, ERK and NFATc2 could co-operatively activate the icos 
promoter. Furthermore, consistent with the data shown in Figure 5B, over-expression of 
caMEK2 could also enhance the promoter activity of mICOSp(−147)-Luc (but not 
mICOSp(−109)-Luc) comparable to that of mICOSp(−288)-Luc, indicating that the ERK-
responsive transcription factors act in this region of the promoter (Figure 3.5C, right 
panel). 
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 Figure 3.5 Transactivation of the putative icos promoter by NFATc2 and ERK 
signalling. 
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A, Delineation of the minimal icos promoter. A series of 5’ truncations of the icos 
promoter was created as shown and linked to a luc reporter gene and transfected into EL4 
cells, which were subsequently stimulated with PMA + iono. Fold induction of luc 
activity was calculated as the ratio of the normalised luc activity of stimulated cells to 
unstimulated cells. B, The activity of the putative icos promoter is affected by CsA and 
U0126 treatment. EL4 cells were transfected in triplicate with mICOSp(−288)-Luc, 
mICOSp(−147)-Luc, or mICOSp(−109)-Luc constructs and stimulated with PMA and 
ionomycin in the absence (white bars) or presence (black bars) of 50 ng/ml CsA (left 
panel) or 50 μM U0126 (right panel). C, Ectopic expression of a constitutively active 
MEK2 or NFATc2 transactivates the minimal icos promoter. EL4 cells were transfected 
in triplicate with mICOSp(−288)-Luc (left and right panels), mICOSp(−147)-Luc or 
mICOSp(−109)-Luc (right panel) together with the indicated expression vectors. Cells 
were either unstimulated (white bars) or stimulated with PMA + iono (black bars) for 
16 h. Fold induction was calculated as the ratio of normalised luc activity of cells over-
expressing the stated protein(s) to cells transfected with null vector. Data shown are mean 
± SEM of triplicate samples and representative of 2 independent experiments. 
* p < 0.05; *** p < 0.001. 
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3.1.6 NFATc2 binds icos 288-bp core promoter in vivo and is affected by Fyn 
signalling 
In order to delineate the cis-regulatory elements contributing to icos core 
promoter activity, we proceeded to search for putative transcription factor-binding sites 
within the 288-bp region by employing the web-based software, MATINSPECTOR 
(www.genomatix.de) and RVISTA 2.0 (http://rvista.dcode.org) (Loots and Ovcharenko, 
2005; Quandt et al., 1995), which are closely interconnected with the TRANSFAC 
database. These programs predicted the presence of potential AP1, C/EBPβ and Ikaros 
but surprisingly, not NFATc binding sites, even though we showed an important role for 
NFATc2 in activating the icos promoter. From the algorithmic predictions, we postulated 
that AP1 could be another candidate that regulates ICOS expression as c-fos was directly 
downstream of ERK in many signalling pathways. However, preliminary experiments 
exploring site-directed mutagenesis of the putative AP1 site (and other sites) within 
mICOSp(−288)-Luc did not lead to reproducible reduction in luc reporter activity. 
Conversely, over-expression of c-fos did not further enhance luc activity in EL4 cells co-
transfected with mICOSp(−288)-Luc (data not shown). 
Since NFATc2 over-expression resulted in increased mICOSp(−288)-Luc activity 
(Figure 3.5C, left panel), we asked if NFATc2 could bind the 288-bp fragment in vivo. 
Using chromatin immunoprecipitation (ChIP) assays, we detected a basal level of 
constitutive binding of NFATc2 to the icos promoter in resting EL4 cells (Figure 3.6A, 
upper panel, lane 5), possibly as a result of deregulated Ca2+ signalling in these cells 
(Fruman et al., 1995). Importantly, this level of binding was substantially increased when 
EL4 cells were stimulated with anti-CD3 and anti-CD28 Abs (lane 6). PP2 treatment on 
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similarly stimulated cells resulted in a reduction in NFATc2 binding (lane 7), suggesting 
that the positive impact of Fyn signalling on ICOS transcription observed earlier is via 
enhancing NFATc2 binding of the icos 288-bp promoter. As a positive control, CsA 
treatment was also observed to diminish, though not to the same extent, NFATc2 binding 
(lane 8). Binding of NFATc2 to the icos promoter was specific as ChIP performed using 
an isotype-matched antibody did not produce visible PCR products (lanes 1 − 4). We also 
examined the binding of NFATc2 to the icos promoter in primary CD4+ T cells lacking 
Fyn (Figure 3.6B). Consistent with the finding that Fyn and NFATc2 act in the same 
signalling axis to activate ICOS transcription, we show that there was reduced binding of 
NFATc2 to the icos promoter in Fyn-/- CD4+ T cells activated by anti-CD3 and anti-
CD28 (lane 8 vs. lane 6). NFATc2 appeared to occupy a region encompassing 230 to 234 
bp of the icos promoter, which contains an imperfectly matching consensus NFAT-
binding sequence, because mutation of the bases between 232 and 231 bp led to a potent 
reduction in promoter activity when NFATc2 is over-expressed (compare luc activity due 




Figure 3.6 ChIP analyses of NFATc2 binding to the icos minimal promoter. 
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A, EL4 cells, either untreated or pre-treated with the indicated inhibitors for 1 h, were 
transfected with NFATc2 vector before stimulation with anti-CD3 and anti-CD28 Abs for 
16 h. Chromatin complexes were immunoprecipitated with either isotype control (upper 
panel, lanes 1 − 4) or anti-NFATc2 Ab (upper panel, lanes 5 − 8) and PCR analyses of 
the region between −288 to −1 of the icos promoter were done on the precipitated DNA. 
To assess for equivalent loading of substrates, the same PCR was performed on serially 
diluted DNA before immunoprecipitation (lower panel). Fold-dilutions of templates are 
indicated on the left. B, Lack of Fyn signalling affects NFATc2 binding to the minimal 
icos promoter. Purified CD4+ T cells from Fyn+/+ and Fyn-/- mice were either 
unstimulated or stimulated with anti-CD3 and anti-CD28 Abs for 16 h and ChIP was 
performed as in A. Results are representative of at least 2 independent experiments. C, 
EL4 cells co-transfected in triplicate with mICOSp(−288)-Luc or 
mICOSp(−288)-NFAT-mut-Luc and NFATc2 were either unstimulated (white bars) or 
stimulated with PMA and iono (black bars). Fold induction was quantitated as in Figure 
3.5C. Data shown are mean ± SEM of triplicate samples and representative of 2 
independent experiments. 
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3.1.7 Identification of an ERK-responsive site in the icos promoter 
Since treatment with U0126 affected ICOS induction in TCR/CD28-stimulated T 
cells apparently at the promoter level, we sought to identify potential ERK-responsive 
site(s) within the icos core promoter region. To this end, we designed a set of overlapping 
double-stranded oligonucleotides which spanned the region 154 bp to 105 bp upstream of 
the icos TSS and used them to compete against nuclear extract binding by this region. As 
shown in Figure 3.7A, left panel, electrophoretic mobility shift assay (EMSA) performed 
with nuclear extracts obtained from P/I-stimulated EL4 cells demonstrated significant 
nuclear complex binding of the icos promoter region spanning 154 bp to 105 bp (lane 2). 
While molar excess of the unlabelled oligonucleotide spanning 129 bp to 105 bp 
(p129_105) failed to compete with the radiolabelled p154_105 (lane 5), the unlabelled 
p154_130 did (lane 4), suggesting that the region between 154 bp and 130 bp upstream of 
icos TSS very likely bound nuclear protein. Using a series of 3-bp scrambled mutations 
along the length of 154 bp to 130 bp, we refined the position of the binding site to 
between 148 bp to 136 bp (data not shown). Moreover, introduction of a 3-bp mutation 
corresponding to 144 bp to 142 bp of p154_130 (p154_p130_mut) interfered largely with 
the ability of unlabelled p154_130_mut to compete with the radiolabelled p154_130 
(Figure 3.7A, right panel, lane 4), suggesting that the integrity of this site is important to 
facilitate optimal binding of as yet undetermined nuclear protein factors. EMSA assays 
revealed that there was considerable induction of complex binding of the stated region to 
nuclear extracts obtained from either P/I-stimulated EL4 cells or TCR/CD28-activated 
murine primary CD4+ T cells compared to those of resting cells (Figure 3.7B, lanes 2 and 
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5 respectively). This binding was reduced dramatically or abrogated in activated EL4 and 
CD4+ T cells pre-treated with U0126 (respectively lanes 3 and 6). 
To confirm the functional relevance of the region spanning 154 bp to 130 bp 
upstream of the icos TSS in responding to ERK signalling, we replicated the above 
described mutation spanning 144 bp to 142 bp in the mICOSp(−288)-Luc construct to 
yield mICOSp(−288)-ERK-mut-Luc and assessed the latter’s reporter activity in EL4 
cells ectopically expressing a constitutively active form of MEK2. Consistent with our 
previous result demonstrating compromised nuclear complex binding, the introduced 
mutation in mICOSp(−288)-Luc led accordingly to a drastic reduction in luc activity 
(Figure 3.7C, left panel). Interestingly, a drastic attenuation in luc activity was also 
observed in EL4 cells over-expressing NFATc2 (Figure 3.7C, right panel), alluding to a 
possible functional hierarchy involving ERK-sensitive transcription factors and NFATc2 
whereby the latter critically requires the former to operate, otherwise its own function is 
crippled. In other words, ERK signalling appears to be extremely important in initiating 
or sustaining basal ICOS transcription, whereas NFATc2 as well as other possible 
transcription factors played a more ancillary role in amplifying transcription. This finding 
is consistent with the failure of exogenous NFATc2 to rescue ICOS transcription in 
U0126-treated EL4 cells (Figure 3.3C) and the earlier purported cooperativity of ERK 
and NFATc2 in signalling ICOS expression (Figure 3.5C, left panel). 
Since the region spanning 154 bp to 130 bp was responsive to ERK signalling, we 
attempted to identify the transcription factor(s) that bind(s) this region. For this purpose, 
we designed a series of unlabelled oligonucleotides bearing consensus DNA sequences 
that were known and had been shown to bind various ERK-sensitive transcription factors 
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such as E26 transformation-specific-1 (Ets-1), E74-like factor-1 (Elf-1), 
E26-like protein-1 (Elk-1), CP2 or late simian virus 40 (SV40) transcription factor (LSF), 
Specificity protein (Sp)1 and AP-1 as well as those recognising NFATc and NF-κB, and 
used these to compete with the binding of nuclear extracts from activated EL4 or CD4+ T 
cells to the icos promoter. None of these unlabelled oligonucleotides convincingly 
competed with the radiolabelled p154_130 in binding the protein complex from activated 
EL4 or CD4+ T cells (Figure 3.7D). Furthermore, the DNA-protein complex did not 
supershift with either anti-c-fos or anti-c-jun Abs (data not shown). Thus, at this juncture, 
we are unable to ascertain the identity of the transcription factor(s), except to report that it 
was or they were responsive to ERK. 
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 Figure 3.7 Identification of an ERK-sensitive site on the icos promoter. 
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A, Demonstration of specific transcriptional complex binding to DNA region -154 to 
-130 of icos promoter. Radiolabelled double-stranded oligonucleotides, p154_105 and 
p154_130, were incubated with nuclear extracts from P/I-stimulated EL4 cells either in 
the presence or absence of excess unlabelled competitors (left and right panels) and 
analysed via EMSA. B, Demonstration that the transcriptional complex binding the 
p154_130 probe is sensitive to the ERK inhibitor. The p154_130 probe was incubated 
with nuclear extracts from EL4 cells (lanes 1 − 3) or CD4+ T cells (lanes 4 − 6) that were 
untreated or treated as stated in the figure, and subjected to EMSA. C, EL4 cells were co-
transfected in triplicate as in Figure 3.6C but with mICOSp(−288)-ERK-mut-Luc and 
caMEK2 (left panel) or NFATc2 (right panel). D, The p154_130 probe was incubated 
with nuclear extracts from PMA and iono-stimulated EL4 cells in the presence or absence 
of excess unlabelled competitors bearing the consensus binding sites of members of 
various transcription factor families; in particular, those that are known to act 
downstream of ERK. ** p < 0.01; *** p < 0.001. 
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3.2 Th lineage-specific regulation of ICOS expression via distinct icos regulatory 
regions by T-bet, GATA-3 and NFATc2 
3.2.1 ICOS is differentially expressed in different Th cell subsets 
To assess if ICOS is differentially expressed in various Th cells, we activated 
primary CD4+ T cells with anti-CD3 and anti-CD28 antibodies (Abs) and differentiated 
them for 8 days under three types of polarising conditions: Th0, Th1, or Th2 (Avni et al., 
2002). These treatment regimes yielded substantial fractions of IFN-γ- and IL-4-
producing cells, indicating that the Th1- and Th2-polarising conditions were optimal 
(Figure 3.8A, right panel). Interestingly, we found the level of surface ICOS expression 
to vary in the different Th cell subsets: Th2 cells, consistent with earlier reports (Coyle et 
al., 2000; McAdam et al., 2000), expressed the highest level of ICOS, followed by Th1 
and Th0 cells (Figure 3.8A, left panel). To determine if this variation in surface 
expression of ICOS could in part be attributed to variation in icos transcript levels, we 
quantified ICOS mRNA levels in the various Th subsets and found that these indeed 
correlated with levels of surface expression, with the highest amount of ICOS mRNA 
found in Th2, followed by Th1 and Th0 cells (Figure 3.8B). The data suggests that the 
expression of ICOS may be under transcriptional control in different Th cells. 
Incidentally, a similar pattern of ICOS protein and mRNA expression was recapitulated 
in AE7 Th1 (Figure 3.8C) and CDC35 Th2 cell clones (Figure 3.8D), confirming 






Figure 3.8 ICOS is differentially expressed in different Th cell subsets. 
 
Purified CD4+ T cells were differentiated for 8 days under Th0, Th1 and Th2-polarising 
conditions and examined for A, cell surface expression of ICOS and, after restimulation 
with PMA and ionomycin for 6 h, for intracellular expression of IL-4 and IFN-γ by flow 
cytometry, and B, ICOS mRNA levels by real-time RT-PCR. Data shown in B had been 
normalised to mRNA levels in naïve T cells and expressed as the mean value ± S.E. of at 
least 3 independent experiments. * p < 0.05; ** p < 0.001; *** p < 0.0001. AE7 Th1 and 
CDC35 Th2 cell clones were left in medium or stimulated with PMA and ionomycin for 
6 h and assessed for C, surface ICOS expression and D, ICOS mRNA levels. Data shown 
in D had been normalised to mRNA levels in untreated AE7 cells and are representative 
of 2 independent experiments. 
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3.2.2 T-bet or GATA-3 enhances ICOS expression in T cells 
Since icos transcripts were expressed differently in different Th cell subsets and in 
particular, at higher levels in Th1 and Th2 cells compared to Th0 cells, we asked if there 
was a role for Th1-specific T-bet and Th2-specific GATA-3, in driving ICOS expression. 
It was shown previously that the Th1-polarising cytokines IL-12 and/or IL-23 could 
enhance ICOS expression in activated human T cells independent of their pre-defined 
differentiation status (Wassink et al., 2004). Similarly, the Th2-polarising cytokine IL-4 
and growth factor IL-2 were shown to regulate ICOS expression in activated CD4+ T 
cells. Although retroviral transduction of GATA-3 was shown to increase surface ICOS 
expression in stimulated murine CD4+ T cells (Yagi et al., 2003), it was not clear if this 
was a direct effect of GATA-3 on icos gene regulation. We therefore sought to ascertain 
if T-bet or GATA-3 per se may directly enhance ICOS expression in the respective Th 
cells. 
To test the individual roles of T-bet and GATA-3 in regulating ICOS expression, 
we first over-expressed these transcription factors in EL4 T cells and measured the level 
of icos transcripts after overnight culture. Real-time RT-PCR analyses indicated that 
ectopic expression of T-bet (Figure 3.9A, left panel) or GATA-3 (right panel) could 
increase the level of icos transcripts in EL4 cells in a dose dependent manner. To control 
for the functionality of T-bet and GATA-3 and as shown in Figure 3.9B, we also 
observed respectively, concomitant increases in ifn-γ and il-5 transcripts in the 
transfected EL4 cells (Siegel et al., 1995; Szabo et al., 2000). Next, we determined if the 
up-regulation of ICOS by T-bet or GATA-3 in EL4 cells was reproducible in primary 
CD4+ T cells. We infected CD4+ T cells activated by anti-CD3/CD28 Abs with 
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retroviruses that expressed GFP alone or together with T-bet or GATA-3 and examined 
ICOS expression in these cells 48 h after infection. Retroviral transduction of T-bet 
(Figure 3.9C, left panel) or GATA-3 (right panel) in activated, non-polarised CD4+ T 
cells led to their corresponding over-expression and also resulted in the higher expression 
of ICOS protein as well as mRNA in these cells when compared with control cells 
transduced with vector expressing GFP alone. 
Finally, to establish definitively that T-bet and GATA-3 play a direct role in 
driving ICOS transcription, we performed converse experiments using small interference 
RNA (siRNA) against T-bet and GATA-3 to knock down their protein expression in AE7 
Th1 and CDC35 Th2 cell lines, respectively. Knock down of Tbx21 and Gata3 transcripts 
led to the efficient abrogation of their protein expression in AE7 (Figure 3.10A) and 
CDC35 (Figure 3.10B) cells, whereas knock down of the irrelevant gfp gene hardly 
affected T-bet expression in AE7 or GATA-3 expression in CDC35 cells. More 
importantly and in agreement with data obtained so far, the knock down of T-bet 
significantly reduced the amount of icos transcripts in activated AE7 cells (Figure 
3.10A), while knock down of GATA-3 profoundly diminished ICOS mRNA in CDC35 
cells (Figure 3.10B). However, the reduction in ICOS mRNA was not absolute, 
suggesting that T-bet or GATA-3 likely cooperates with other transcription factors to 
regulate ICOS expression. Taken together, our over-expression and siRNA knock down 
data indicate that T-bet and GATA-3 play enhancing roles in driving ICOS transcription 







 Figure 3.9 Ectopic expression of T-bet or GATA-3 enhances ICOS expression in 
T cells. 
 
Real-time RT-PCR analyses of A, ICOS and B, IFN-γ and IL-5 mRNA levels in murine 
EL4 T cells transfected with null vector or increasing amounts of vectors encoding for 
either T-bet or GATA-3. * p < 0.05; ** p < 0.001; *** p < 0.0001. Data shown in B are 
representative of at least 2 independent experiments. C, Flow cytometry and real-time 
RT-PCR analyses of ICOS expression in purified CD4+ T cells transduced with 
retroviruses encoding GFP (GFP-RV), GFP and T-bet (T-bet-RV) or GFP and GATA-3 
(GATA-3-RV). Only GFP+ cells were examined for ICOS expression by flow cytometry 
and FACS-sorted for the analysis of icos transcript levels. * p < 0.05; ** p < 0.001. 
Western blots were included to show over-expression of T-bet or GATA-3 in the 
retrovirally transduced samples. The anti-ERK-2 blot served as control for equal loading 




Figure 3.10 Knockdown of T-bet or GATA-3 reduces icos transcripts in AE7 Th1 
and CDC35 Th2 cell lines. 
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A, AE7 Th1 or B, CDC35 Th2 cells were transfected with siRNA against GFP (as 
control), T-bet or GATA-3, rested for 24 h and stimulated with PMA and ionomycin for 
16 h. The amount of icos transcripts present was assessed by real-time RT-PCR. The 
knockdown efficiencies in these cells were assessed by Western blotting as shown. The 
anti-ERK2 blot serves as loading control. ** p < 0.001. 
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3.2.3 T-bet is more dominant in activating ICOS transcription in developing 
rather than fully differentiated Th1 cells 
To establish a physiological role for T-bet in ICOS expression during Th1 
development, we first cultured T-bet-sufficient (T-bet+/+) and T-bet-deficient (T-bet-/-) 
CD4+ T cells under Th1-polarising conditions and compared the cell surface ICOS 
expression in developing (Figure 3.11A) or fully differentiated cells (Figure 3.11B). After 
2 days of culture, T-bet+/+ CD4+ T cells exhibited surface ICOS expression that was 
comparable to that in T-bet-/- cells (Figure 3.11A). In contrast, ICOS mRNA levels were 
significantly reduced in developing T-bet-/- Th1 cells, even though the proportion of 
T-bet-/- cells producing IFN-γ is similar to their T-bet+/+ counterparts. Hence, T-bet 
deficiency results in attenuated ICOS transcription in developing Th1 cells, at a stage 
when T-bet-associated defects in IFN-γ production are not yet apparent. 
Surface ICOS expression of fully differentiated T-bet-/- T cells were observed to 
be marginally lower than that of T-bet+/+ cells (Figure 3.11B). Unlike developing cells, 
the fraction of committed T-bet-/- Th1 cells that are IFN-γ+ was moderately reduced as 
compared to similarly cultured T-bet+/+ cells (Figure 3.11B). There was, however, no 
significant difference in ICOS mRNA levels between terminally differentiated T-bet+/+ 
and T-bet-/- Th1 cells. Thus, our data suggest a non-trivial role for T-bet in driving ICOS 
transcription particularly during the early Th1 ontogeny. However, this role of T-bet 
appears to diminish in importance as the cells approach terminal differentiation, 
indicating other factors may be involved in regulating ICOS transcription and could 
compensate for the absence of T-bet during the later phase of Th1 development. One 
such possible factor is ERK, the signalling of which we had earlier shown to be important 
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for activating basal ICOS transcription in TCR/CD28-stimulated T cells. Since the level 
of ERK phosphorylation (and hence activity) was perceptibly higher in the nuclei of 
differentiated T-bet-/- compared to T-bet+/+ Th1 cells (Figure 3.12B), exacerbated nuclear 
ERK activity in T-bet-/- Th1 cells might account for comparable amounts of icos 
transcripts in T-bet+/+ and T-bet-/- Th1 cells (Figure 3.11B). Nuclear occupancy of 
phospho-ERK in both developing T-bet+/+ and T-bet-/- Th1 cells occurred with faster 
kinetics than Th0 or Th2 cells (Figure 3.12A), which could explain in part why ICOS 
transcription is not completely abolished in developing Th1 cells lacking 
T-bet (Figure 3.11A). Although it is presently unclear why T-bet deficiency leads to 
enhanced nuclear phospho-ERK in differentiated Th1 cells, our observation of sustained 
ERK activation in Th1 cells is consistent with a study using a high affinity peptide for 
stimulation of CD4+ T cells that maintained ERK activation and resulted in Th1 
differentiation. If a cognate peptide of lower affinity was employed, transient ERK 
activity which followed dramatically increased IL-4 production and Th2 generation. 
(Jorritsma et al., 2003). We observed comparatively less enduring nuclear ERK activity 
in developing and differentiated Th2 cells (Figure 3.12A and B). Admittedly, 
interpretation of the role of nuclear phospho-ERK in T-bet+/+ vs. T-bet-/- Th1 cells 
undergoing differentiation, with the currently available evidence, is at best correlative 
and further experiments are required to clarify how ERK signalling influences ICOS 
transcription during Th1 development. 
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 Figure 3.11 The amount of icos transcripts is reduced in the absence of T-bet in 
developing but not fully differentiated Th1 cells. 
 
T-bet+/+ and T-bet-/- CD4+ T cells were differentiated for A, 2 days or and B, 8 days 
under Th1-polarising condition and examined for cell surface ICOS expression or, after 
restimulation with PMA and ionomycin for 6 h, intracellular IFN-γ and IL-4 expression 
by flow cytometry. Data shown are representative of 3 independent experiments. The 
levels of ICOS mRNA in Th1 cells, assessed by real-time RT-PCR, had been normalised 
to those in naïve CD4+ T cells and expressed as the mean value ± S.E. of 3 independent 





Figure 3.12 Nuclear translocation of NFATc2 precedes that of phospho-ERK in 
developing Th cells. 
 
T-bet+/+ and T-bet-/- CD4+ T cells were differentiated for A, 2 days or B, 8 days under 
Th0, Th1 or Th2-polarising conditions. Nuclear extracts were prepared from these cells 
and subjected to immunoblotting with anti-phospho-ERK, anti-T-bet, anti-GATA-3 and 
anti-NFATc2. The anti-ERK2 blot serves as control for equal loading of extracts. The 
anti-HDAC-1 and anti-β-actin blots indicate the effectiveness of separation between 
nuclear and cytoplasmic fractions. 
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3.2.4 T-bet cooperates with NFATc2 to transactivate the icos promoter 
Since T-bet and GATA-3 are transcription factors shown to transactivate the 
promoters of ifn-γ (Szabo et al., 2000) and il-5 (Zhang et al., 1997) genes respectively, 
we were interested to determine if they would also regulate icos gene expression via 
binding to its promoter region. Initial algorithmic searches using the TRANSFAC 
database did not reveal putative binding sites for T-bet or GATA-3 in the icos promoter. 
We had previously shown that NFATc2 enhanced ICOS expression by acting within a 
288-bp promoter region upstream of the ICOS transcription start site (TSS) (Figures 
3.13A, 3.5C and Tan et al., 2006). Hence, to find out if this region could respond to T-bet 
and/or GATA-3, we introduced a luc reporter plasmid driven by the 288-bp icos 
promoter, with or without accompanying plasmids encoding T-bet, NFATc2 or both, into 
EL4 cells by transient transfection. 
Ectopic expression of NFATc2 led to an increase in icos promoter activity as 
reflected by the fold induction of luc activity in PMA/ionomycin-activated EL4 cells 
(Figure 3.13B), concordant with our earlier work demonstrating that NFATc2 regulates 
ICOS expression. The introduction of T-bet also resulted in the up-regulation of luc 
activity in stimulated EL4 cells, suggesting that T-bet acted via the icos promoter to 
activate gene expression. Interestingly, the effect produced by co-introduction of T-bet 
and NFATc2 was additive, implying T-bet cooperates with NFATc2 at the promoter to 
drive transcription. 
 
3.2.5 GATA-3 synergises with NFATc2 to regulate gene expression via an icos 
3′UTR element 
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We repeated the above experiments to determine if GATA-3 could also act via the 
promoter to regulate ICOS expression. In contrast to T-bet, we observed that ectopic 
expression of GATA-3 could not enhance icos promoter activity beyond what was 
observed with null vector control (Figure 3.13D, left panel). This suggests the icos 
promoter does not possess GATA-3-responsive elements. 
In order to delineate where GATA-3 might act in the icos genomic locus, we 
searched for potential GATA-3 binding motifs and identified a cluster of conserved 
GATA-3 and NFATc2 binding sites within a 259-bp stretch in the 3′-untranslated region 
(3′UTR) of icos (Figure 3.13A). To test the functional relevance of this 3′UTR site, we 
cloned the 259-bp fragment downstream of a luc reporter driven by a previously 
described 52-bp minimal icos promoter, and introduced this construct into EL4 cells. 
Stimulation of EL4 cells harbouring this construct resulted in a 40-fold induction of luc 
activity (Figure 3.13C, null vector), suggesting that this 259-bp segment was sufficient to 
confer PMA and ionomycin-mediated inducibility on ICOS transcription. To determine if 
this element could respond to T-bet and/or GATA-3, we co-transfected, together with the 
259-bp 3′UTR reporter, vectors expressing NFATc2, GATA-3 and T-bet in EL4 cells. 
Over-expression of either GATA-3 or NFATc2 could augment the 3′UTR activity by 
approximately 150- and 100-fold, respectively. Strikingly, the co-expression of GATA-3 
and NFATc2 resulted in > 500-fold increase in luc activity, suggesting GATA-3 
synergises with NFATc2 to enhance ICOS transcription via this 3′UTR site. On the other 
hand, over-expressing T-bet failed to yield an increase in 3′UTR activity (Figure 3.13D, 
right panel), indicating that this region was probably non-responsive to T-bet. Hence, 









Figure 3.13 T-bet and GATA-3 act through distinct icos regulatory regions to 
regulate gene expression. 
 
A, Schematic diagram showing putative regulatory regions within the icos gene locus. 
The promoter (P), transcription start site (TSS) and 5′ and 3′ untranslated regions (UTRs) 
are depicted. B, T-bet or NFATc2 acts alone and also cooperatively with each other to 
transactivate the icos promoter. EL4 cells were transiently transfected in triplicate with a 
luc reporter driven by the 288-bp icos promoter together with either a null vector or 
vector encoding T-bet, NFATc2 or both and subsequently left in medium alone (white 
bars) or stimulated with PMA and ionomycin (black bars) for 16 h. Fold induced luc 
activity was calculated as in Materials and Methods. C, GATA-3 and NFATc2 act 
synergistically via a 3′UTR element to transactivate icos expression. EL4 cells were 
transfected in triplicate with a 52-bp minimal icos promoter-driven luc reporter and a 
259-bp 3′UTR segment together with either a null vector or vector encoding GATA-3, 
NFATc2 or both. Fold induced activity was quantified as in B. D, Over-expression of 
GATA-3 or T-bet does not enhance the activity of icos promoter or 3′UTR element, 
respectively. EL4 cells were transiently transfected in triplicate with luc reporter driven 
by the 288-bp icos promoter with null or GATA-3 vector, or 259-bp 3′UTR together with 
null or T-bet vector and subsequently left in medium alone (white bars) or stimulated 
with PMA and ionomycin (black bars) for 16 h. Fold induction was measured as in B. 
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3.2.6 Differential association of T-bet/NFATc2 with icos promoter and 
GATA-3/NFATc2 with icos 3′UTR during Th1 and Th2 differentiation, 
respectively 
Data from the luc assays suggest that ICOS may be regulated distinctly in 
different Th cell subsets, likely with T-bet acting at the promoter and GATA-3 at the 
3′UTR in Th1 and Th2 cells respectively and, with NFATc2 acting as the common co-
activator in both Th subsets. Indeed, NFATc2 has been reported to cooperate with T-bet 
or GATA-3 in binding the regulatory regions of the ifn-γ gene in stimulated Th1 (Lee et 
al., 2004a) or the il-4 gene in stimulated Th2 cells (Agarwal et al., 2000), respectively. 
We therefore asked if T-bet, GATA-3 and NFATc2 differentially associated with the 
different icos regulatory regions during Th cell development. This was addressed by 
assessing the binding dynamics of T-bet, GATA-3 and NFATc2 to icos regulatory 
regions in developing and fully differentiated Th1 and Th2 cells. 
ChIP assays revealed detectable binding of T-bet to the icos promoter (icos P) in 
developing (2-day culture) Th1 cells after stimulation of these cells for 6 h with PMA and 
ionomycin (PMA + iono) (Figure 3.14A, lanes 3 and 4). This binding was significantly 
elevated in fully differentiated (8-day culture) Th1 cells and could be further enhanced 
when the cells were stimulated (lanes 9 and 10). On the other hand, T-bet was not 
observed to bind the promoter in developing or differentiated Th0 (lanes 1, 2, 7 and 8) 
and Th2 (lanes 5, 6, 11 and 12) cells, consistent with the virtual absence of T-bet 
expression in these cells (Figure 3.12A and B). Similarly, binding of GATA-3 to the 
3′UTR element of icos was evident after 2 days of culture in developing Th2 cells (Figure 
3.14A, lanes 17 and 18). This association was greatly augmented in Th2 cells that 
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approached terminal differentiation after 8 days of culture, and could be further enhanced 
upon activation of these cells (lanes 23 and 24). Again, GATA-3 binding to the 3′UTR of 
icos was undetectable in developing or differentiated Th0 (lanes 13, 14, 19 and 20) or 
Th1 cells (lanes 15, 16, 21 and 22), in agreement with the preferential expression of 
GATA-3 in Th2 cells (Figure 3.12A and B). 
Binding of NFATc2 to the icos promoter was detectable in Th0 cells cultured for 
2 days and can be further increased when cells were stimulated (Figure 3.14B, lanes 1 
and 2), in accordance with our previous demonstration that NFATc2 was found to be 
associated with the promoter during anti-CD3/CD28-mediated activation of naïve CD4+ 
T cells. Intriguingly, the association of NFATc2 with the icos promoter was found 
initially to be promiscuous across developing Th cells (lanes 1 to 6), but became 
progressively Th1-restricted, Th0-diminished and Th2-extinguished as cells became 
terminally differentiated (lanes 7 to 12). On the other hand, the binding of NFATc2 to the 
3′UTR of icos was marginally detectable in various developing Th cells at an early stage 
of differentiation (lanes 13 to 18) but became conspicuous and specifically accrued in 
terminally differentiated Th2 cells (lanes 23 and 24). Given the rapid nuclear localisation 
of NFATc2 upon TCR/CD28 stimulation and the maintenance of NFATc2 nuclear 
residency during the course of Th differentiation (Figure 3.12A and B), such a temporally 
dynamic pattern of NFATc2 association with the icos regulatory DNA suggests the 
involvement of epigenetic mechanisms that educate accessibility of the icos regulatory 
regions to transcription factors. 
Taken together, the evolving patterns of T-bet, GATA-3 and NFATc2 binding to 
the promoter and 3′UTR of icos supports a model in which NFATc2 functions as the 
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major common transcription factor driving ICOS expression via the promoter during 
early Th differentiation when TCR-mediated signalling is dominant and cytokine 
pathways are nascent. As Th differentiation progresses and the influence of polarising 
cytokines increases, T-bet cooperates with NFATc2 to direct ICOS expression via its 
promoter in Th1 cells, while GATA-3 synergises with NFATc2 to regulate ICOS 









Figure 3.14 Differential association of T-bet, GATA-3 and NFATc2 with the icos 
regulatory regions during de novo Th1 and Th2 cell differentiation. 
 
ChIP assays using Abs against A, T-bet and GATA-3 and B, NFATc2 were performed on 
primary CD4+ T cells differentiated for 2 or 8 days under Th0-, Th1- or Th2-polarising 
conditions and left in medium or restimulated for further 6 h with PMA and ionomycin. 
Primers specific for the icos promoter (P) or 3′UTR element (3′UTR) were used in the 
PCR. As input controls, DNA extracted from the samples before immunoprecipitation 
was serially diluted (1/10 and 1/50) and quantified by the same PCR. 
Immunoprecipitation with isotype-matched control Abs did not yield visible PCR bands 
(not shown for brevity). 
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3.2.7 Histone trimethylation of icos regulatory regions is Th-selective 
Our data above revealed a temporally changing yet Th-selective pattern of 
binding by transcription factors to distinct icos regulatory regions in various Th cell 
subsets. It is plausible that this intricate pattern of binding by transcription factors could 
be influenced by epigenetic mechanisms that operate in concert to induce ICOS 
expression in Th cells. Hyperacetylation of histones H3 and H4 is a major mechanism 
through which cytokine signalling pathways preserve the transcriptional permissiveness 
of genes encoding the cytokines themselves in mouse and human Th cells (Ansel et al., 
2006; Baguet and Bix, 2004; Morinobu et al., 2004; Mullen et al., 2001). For example, 
TCR stimulation of naïve T cells resulted in a transient increase in histone acetylation of 
the ifn-γ and il-4 regulatory regions, which was stabilised by polarizing cytokines such as 
IL-12 and IL-4 that were required to promote Th1 and Th2 differentiation respectively 
(Avni et al., 2002). Based on these observations, we postulated that histones associated 
with the icos regulatory regions might undergo Th-specific modification by either 
acetylation or trimethylation, thereby increasing the availability of these regions to 
binding by T-bet, GATA-3 and/or NFATc2. 
To test this hypothesis, we examined histone trimethylation at the icos locus using 
an antibody that recognised trimethylated histone H3 lysine residue 4 (K4). Interestingly, 
a similar degree of histone trimethylation was detected across all Th subsets after 2 days 
of differentiation. This suggests a non-selective accessibility of the icos promoter (Figure 
3.15, lanes 1 to 6) and 3′UTR region (lanes 13 to 18) during the early phase of Th 
differentiation. However, as differentiation proceeded, the pattern of histone H3 
trimethylation at the icos locus evolved in a Th-specific manner. Hypermethylation of H3 
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was selectively enhanced at the icos promoter in differentiated Th1 (lanes 9 and 10) but 
not Th0 (lanes 7 and 8) or Th2 (lanes 11 and 12) cells. In contrast, an increase in H3 
trimethylation was apparent only at the 3′UTR of icos in Th2 cells (lanes 23 and 24), but 
was less so in Th0 cells (lanes 19 and 20) and completely obscured in Th1 cells (lanes 21 
and 22). These patterns of chromatin accessibility at the icos promoter and 3′UTR region 
strikingly resembled those of T-bet, GATA-3 and NFATc2 binding of these regions in 
Th1 and Th2 cells. We thus propose that such epigenetic modification of the icos locus 
could provide a mechanistic explanation for the dynamic binding of, especially, NFATc2 
to icos regulatory DNA, as the selective association of T-bet and GATA-3 to the same 
regions may be ascribed largely to their lineage-restricted expression. 
Taken together, our data unequivocally show that the accessibility of icos 
regulatory regions in different Th subsets is amenable to regulation by histone 
modification and that the binding pattern of transcription factors to these regions mirrored 






Figure 3.15 Active ICOS transcription correlates with the chromatin accessibility 
of the icos promoter or 3’UTR during Th cell differentiation. 
 
ChIP assays using an Ab recognizing trimethylated histone H3 lysine 4 (anti-H3K4me3) 
were performed on CD4+ T cells that were differentiated for 2 or 8 days under Th0-, 
Th1- or Th2-polarizing conditions and left in medium or restimulated with PMA and 
ionomycin. Primers specific for the icos regulatory regions (as in Figure 5) were used in 
the PCR. Immunoprecipitation using rabbit serum as control yielded negative results (not 
shown). The same PCR was also performed on input DNA to control for loading of 
samples. 
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3.3 Post-transcriptional regulation of ICOS expression by RING-type E3 
ubiquitin ligase, roquin 
In addition to regulation of ICOS expression at the transcriptional level, there may 
exist mechanisms that regulate ICOS at the post-transcriptional level. Roquin was first 
identified, in a forward genetics approach to screen for autoimmune phenotypes 
generating high titers of antinuclear autoantibodies, as a novel RING-type E3 ubiquitin 
ligase responsible for repressing self-reactive TFH cells. A methionine (M) to arginine (R) 
(sanroque) mutation in a highly conserved novel protein domain (ROQ domain) of this 
protein results in excessive numbers of TFH cells and GCs in sanroque mice, which 
subsequently developed a lupus-like pathology (Vinuesa et al., 2005a). Other RING-type 
ligases important in the induction and maintenance of T cell anergy and immune self-
tolerance include c-Cbl, Cbl-b, and GRAIL (Mueller, 2004). Importantly, one of the 
targets that roquin negatively regulates may be ICOS as sanroque CD4+ T cells, whether 
CD44high or CD44low, over-express surface ICOS (Vinuesa et al., 2005a). We therefore 
hypothesised that since roquin contains a CCCH zinc finger domain shared by RNA-
binding proteins such as TTP and Pos-1, it may, via binding its 3′UTR region, regulate 
ICOS mRNA stability. Alternatively, the prediction of a RING-finger in roquin suggests 
that it could regulate ICOS protein stability by ubiquitin-mediated proteasomal 
degradation. To test these hypotheses, we performed preliminary experiments to examine 
the role of roquin in regulating ICOS expression. 
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3.3.1 Roquin negatively regulates ICOS mRNA stability 
To test whether roquin negatively regulates ICOS mRNA stability, we over-
expressed null vector, roquin WT or roquin M199R in EL4 cells and examined ICOS 
mRNA levels after overnight culture. Enforced expression of roquin WT in EL4 cells 
dose-dependently depressed ICOS mRNA levels below those observed with null vector 
control. On the other hand, over-expression of roquin M199R produced a more modest 
dampening of ICOS mRNA (Figure 3.16A), perhaps consistent with sanroque mutation 
being recessive. We next performed similar experiments but treated the cells with 
actinomycin D to block de novo gene transcription before assessing ICOS mRNA levels 
over a time course. The decay of icos transcripts in cells over-expressing roquin WT 
occurred more rapidly than in cells harbouring null vector control. Suprisingly, icos 
transcripts in cells bearing roquin M199R appeared to decay marginally less slowly than 
null vector control, suggesting the sanroque mutation in this case to be dominant 
negative. However, over-expression of roquin M199R, resulting in copies greatly 
outnumbering the endogenous WT copies, may have caused such an effect, necessitating 
caution in interpretation of the M199R decay results. 
Taken together, our results suggest that roquin may promote the destabilisation of 




Figure 3.16 The level of icos transcript is more severely diminished by ectopic 
expression of roquin WT than M199R mutant in EL4 cells. 
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A, EL4 cells transfected with null vector, roquin WT or M199R mutant were stimulated 
with plate-bound anti-CD3 (1 μg/ml) plus anti-CD28 (4 μg/ml) and harvested after 16 h 
of culture. RNA was isolated from these cells and subjected to real-time RT-PCR 
analysis for ICOS. Levels of ICOS mRNA were normalised to those of β-actin. B, EL4 
cells were transfected and stimulated as above for 6 h before actinomycin D (10 μg/ml) 
was added and total RNA isolated after 0, 30, 60, 120 and 180 min. 
The normalised ICOS mRNA levels in cells A, transfected with null vector, or B, at time 
0 was taken to be 100% and all other normalised mRNA levels were graphed relative to 
that value. Data shown are mean values ± SEM of triplicate samples and representative of 
at least 2 independent experiments. On a log scale, the points can be fitted to a one-phase 












 4.1 Transcriptional regulation of ICOS during early phase of T cell activation 
when TCR/CD28 co-stimulation is dominant 
ICOS is a member of the CD28 superfamily of costimulatory receptors that is 
expressed at low levels on naïve T cells but rapidly up-regulated on activated T cells. 
Although the in vivo functions of ICOS in health and disease are well characterised, very 
little is known about the molecular mechanisms that regulate ICOS expression. In this 
study, we present evidence that during the initial phase of T cell activation when TCR 
and CD28 co-stimulatory signals are dominant, the Fyn-calcineurin-NFATc2 and MEK2-
ERK1/2 signalling pathways cooperate to induce ICOS expression. 
We first demonstrated that there was a direct correlation between the up-
regulation of ICOS cell surface expression and the induction of its mRNA, suggesting 
that TCR/CD28 signalling directly regulate ICOS expression at the transcriptional level. 
Both TCR and CD28 stimulation are known to activate a number of downstream 
signalling molecules, and it is expected that not all of them are involved in regulating 
ICOS. T cells possess both the Syk and Src family of tyrosine kinases, which are 
important in proximal TCR signalling. Our data indicate that Src family tyrosine kinases 
play a major role in TCR-mediated ICOS induction. Of the two major Src kinases present 
in T cells, namely Lck and Fyn, the latter seems to be critical for inducing ICOS. This 
reflects a non-redundancy of the two kinases in an important aspect of T cell physiology. 
Consistent with the fact that CD28 co-stimulation is known to activate the NFAT 
family of transcription factors, our results clearly demonstrate an important role for 
NFATc2 in activating ICOS transcription (Figures 3.3, 3.5 and 3.6). TCR engagement is 
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known to activate the Ca2+/calmodulin-dependent serine phosphatase, calcineurin, which 
dephosphorylates NFAT proteins and leads to their translocation into the nucleus. 
Nuclear NFAT has been shown to activate cytokine gene (e.g. il-2) promoters and 
enhancers, resulting in positive T cell responses (reviewed in refs. (Hogan et al., 2003; 
Macian et al., 2001)). Our studies expand these previous findings and implicate an 
additional nontrivial role for the calcineurin-NFATc2 pathway in up-regulating ICOS 
transcription. This was supported by our data showing the ability of the 
immunosuppressive drug CsA in blocking ICOS induction at both the cell surface 
receptor and mRNA levels (Figure 3.2A, B and E) and affecting icos promoter activity 
(Figure 3.5B, left panel). Moreover, exogenously expressed NFATc2 could enhance 
ICOS mRNA levels (Figure 3.3B) and promoter activity (Figure 3.5C, left panel). Thus, 
NFATc2 is involved in regulating ICOS expression. 
The attenuation of NFATc2 nuclear translocation and in vivo occupation of the 
icos promoter region following PP2 treatment of activated T cells and the ability of 
NFATc2 over-expression to overcome PP2 inhibition of ICOS induction in activated EL4 
cells places NFATc2 downstream of Fyn in the signalling axis that induces ICOS 
expression. Indeed, evidence that binding of the icos promoter by NFATc2 is 
compromised in Fyn-/- CD4+ T cells provided further support for the presence of a Fyn-
calcineurin-NFATc2 signalling axis that regulates ICOS transcription. 
Other major pathways activated by TCR and CD28 signalling include those 
involving MAPKs, of which ERK appears to play a major role in ICOS induction. This is 
inferred from the efficiency of the pharmacological inhibitor U0126 (but not p38 
inhibitor SB203580 or JNK inhibitor I) to block surface ICOS (Figure 3.2A) and mRNA 
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(Figure 3.2B and E) up-regulation, as well as almost ablating icos promoter activity 
(Figure 3.5B, right panel). Co-transfection assays with a constitutively active form of 
MEK2 (caMEK2) demonstrated that over-expressed caMEK2 enhanced ICOS 
transcription (Figure 3.3A) and promoter activity (Figure 3.5C). Although we eventually 
identified a functional target site residing within 148 to 136 bp of the icos promoter 
region responsive to ERK signalling (because mutation of this site severely dampened 
reporter activity in caMEK2-over-expressed EL4 cells as shown in Figure 3.7D), it is far 
from clear what the identity of the transcription factors that bind this region are. Further 
investigation has to be carried out to determine the identity of these factors. 
Our current findings also seem to suggest that ERK signals independently and 
critically to regulate ICOS expression as the over-expression of NFATc2 could not rescue 
the U0126-mediated block in ICOS induction (Figure 3.3C). Intriguingly, the ERK-
responsive transcription factors appear to occupy an icos promoter region that is different 
from that recognised by NFATc2. The over-expression of NFATc2 and caMEK2 
synergistically induce ICOS expression at the mRNA level. Finally, mutation of the 
ERK-sensitive site within the icos promoter not only significantly impaired the ability of 
ERK but also NFATc2 in driving high levels of ICOS transcription. These data 
collectively support a model of two signalling pathways, namely Fyn-calcineurin-
NFATc2 and MEK2-ERK1/2, that independently converge on the icos promoter to 
regulate transcription, with the added complexity that ERK signalling critically initiates 
ICOS transcription, while NFATc2 augments the ERK-initiated signal. 
The study of the transcriptional regulation of ICOS is of immense importance as 
the human chromosome region 2q33 that harbours the costimulatory cluster of CD28, 
97 
ICOS and CTLA-4 genes has been linked to a number of autoimmune diseases. Sequence 
alignment of regions flanking the first coding exon of the mouse and human icos genomic 
DNA revealed two zones of sequence homology separated by a ∼250-bp mouse-specific 
repetitive DNA region (Ling et al., 2001). Interestingly, we found that the 288-bp region 
defined in this report to possess promoter activity is located within the mouse-specific 
repetitive region, implying possible differences in the regulation of mouse as compared to 
human ICOS transcription. Indeed, while ICOS plays an important role in the 
development of and is preferentially expressed in mouse Th2 cells (Arimura et al., 2002; 
Nurieva et al., 2003a), its expression appears to be enhanced in human Th1 cells 
(Wassink et al., 2004), although a recent study determined that polymorphisms in the 
human icos promoter are significantly associated with allergic sensitisation and Th2 
cytokine production (Shilling et al., 2005). It is possible that any variants found within 
the mouse icos promoter could adversely impact NFATc2 and/or ERK-mediated 
transcription factor binding, leading to aberrant ICOS transcription and Th-skewing. In 
terms of polymorphisms in the icos locus associated with susceptibility to autoimmune 
diseases, a large family-based association study linked the short genomic interval 
encompassing the cd28-ctla-4-icos locus on human chromosome 2q33 to systemic lupus 
erythematosus susceptibility in two genome-wide linkage scans (Graham et al., 2006). 
The same gene region subjected to transmission/disequilibrium tests with coeliac disease, 
a common multifactorial disease, indicated that four polymorphisms, all located in the 
icos gene, showed evidence for genetic association (Haimila et al., 2004). Another study, 
using multiethnic DNA panels that represented a wide spectrum of human populations, 
demonstrated long-range linkage disequilibrium among the cd28, ctla-4 and icos genes. 
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A large fraction of the variation found at the cd28, ctla-4 and icos promoter could be 
attributed to the presence of extended haplotypes shaped by demographic events, 
environmental adaptation and/or microbial encounter (Butty et al., 2007). What these 
longitudinal studies emphasise is the relevance of polymorphisms in the icos cis-
regulatory regions to interpreting its association with immune/autoimmune 
responsiveness. Of course, not all polymorphisms identified have functional significance. 
For example, no association of the microsatellite polymorphisms in the icos gene with 
susceptibility to type 1 diabetes was found when screening the IDDM12 locus (coincident 
with cd28-ctla-4-icos locus) on human chromosome 2q33 (Ihara et al., 2001). 
Homologous to the human cd28-ctla-4-icos locus, linkage analysis and congenic 
mapping in NOD mice have identified a syntenic region containing ctla-4 and icos genes 
that is a susceptibility locus for type 1 diabetes, Idd5.1, on mouse chromosome 1. Higher 
ICOS and lower full-length CTLA-4 expression were observed on activated NOD T cells 
compared with C57BL/6 (B6) and C57BL/10 (B10) T cells, correlating with greater 
IL-10 production which may be responsible for the less severe EAE in NOD mice 
although they are predisposed to diabetes (Greve et al., 2004). This is an example par 
excellence illustrating that variations in the cd28-ctla-4-icos locus has direct effects on 
ICOS protein expression in T cells, underscoring the importance of delineating icos 
regulatory regions. Differences in ICOS expression, brought about by differences in its 
transcriptional regulation, could influence immune responses in allergic and autoimmune 
disease conditions. 
In conclusion, this work has defined two molecular pathways downstream of TCR 
and CD28 signalling, namely Fyn-calcineurin-NFATc2 and MEK2-ERK1/2, in the 
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regulation of mouse ICOS transcription (Figure 4.1). Furthermore, we demonstrated the 
binding of ICOS promoter by NFATc2 and delineated an ERK-responsive site in the 
promoter which likely binds yet-to-be-identified transcription factors. Because ICOS 
plays an important role in the pathogenesis of many diseases, understanding the 
molecular mechanisms by which ICOS is regulated may present new opportunities for 
therapeutic intervention of pathologies involving this costimulatory molecule. In this 
regard, our current studies could shed light on human studies investigating the association 
of autoimmune diseases such as multiple sclerosis and type I diabetes with 
polymorphisms in the cd28/ctla-4/icos gene cluster briefly discussed above. Future work 
will centre on discovering other possible signalling pathways and transcription factors 
that regulate ICOS expression, especially those signalling pathways associated with the 
polarisation of T cells into different T cell subsets, which was carried out in the second 






Figure 4.1 Proposed model for transcriptional regulation of ICOS expression by 
Fyn-calcineurin-NFATc2 and MEK2-ERK1/2 signalling in T cells. 
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4.2 Transcriptional regulation of ICOS during T cell differentiation when 
lineage-determining cytokines and transcription factors are dominant 
Early studies interrogating the roles of costimulatory molecules such as CD28, 
CTLA-4, ICOS and PD-1 in Th differentiation attempted to define precisely the 
contribution of each receptor to the specification of a certain lineage fate (Dong et al., 
2003; Greenwald et al., 2005). ICOS, as mentioned earlier, was initially believed to be 
more important for Th2-type immune responses as ICOS deficient T cells exhibited 
defects in mediating B-cell antibody class switching to IgG1 and IgE during the primary 
response to protein antigen in vivo and in producing IL-4 when restimulated by the same 
antigen in vitro, although they produced normal or enhanced levels of IFN-γ (Dong et al., 
2001a; Tafuri et al., 2001). A report subsequently confirmed tight correlation between 
ICOS expression in CD4+ T cells and their production of Th2-biased cytokines (Lohning 
et al., 2003). Such a heightened importance for ICOS in Th2-driven immunity was 
evident from parasitic infection models: ICOS exerts considerable control of protective 
Th2 responses against Leishmania major and Nippostrongylus brasiliensis. Genetic 
ablation of this costimulatory pathway in or its inhibition by administration of 
anti-B7RP-1 mAb to mice significantly suppressed IL-4, IL-5 and IL-10 secretion from 
lymph node cells and serum IgE levels (Miyahira et al., 2003). More recently, it was 
found that ICOS does not appear to maintain a chronic cellular Th2 response during live 
infection by the filarial nematode, Brugia malayi, as the development of IL-4 producing 
Th2 cells and eosinophil recruitment were normal in ICOS deficient mice. Rather, in a 
chronic helminth infection, the primary function of ICOS might be to drive antibody 
switching toward type 2 isotypes, as this component of the immune response was 
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defective (Loke et al., 2005). Despite substantial evidence implicating ICOS in Th2 
responses, numerous other studies suggest ICOS plays a nontrivial role in some Th1-
mediated pathologies, most notably autoimmune disorders and graft-versus-host disease 
(GVHD). For instance, blockade of ICOS/B7-H2 interaction during different phases of 
EAE produced reciprocal disease outcomes (Rottman et al., 2001). ICOS blockade by 
treatment with anti-B7RP-1 mAb or genetic inactivation substantially reduced clinical 
progression of murine experimental autoimmune uveoretinitis (Usui et al., 2006b). 
Similar ICOS inhibition in mice afflicted with GVHD suppressed intragraft T cell 
activation and cytokine production, resulting in prolonged allograft survival (Ozkaynak et 
al., 2001), whereas targeting of ICOS expressed on alloreactive donor T cells inhibited 
GVHD and promoted bone marrow engraftment in recipient mice (Taylor et al., 2005). 
ICOS signalling appears to function differently in humans compared to mice. Human 
recipients of alloreactive T cells lacking ICOS during an allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) demonstrated significantly less GVHD morbidity and 
mortality as these ICOS deficient T cells were deviated toward a Th2 phenotype 
(Hubbard et al., 2005). In addition, unlike mouse deficiency in ICOS, human deficiency 
was reported to compromise naïve, switched and memory B cell generation while 
preserving T cell subset distribution, and is associated with common variable 
immunodeficiency or CVID (Grimbacher et al., 2003; Warnatz et al., 2005). 
There are also studies suggesting that ICOS controls Th cell polarisation and not 
merely the function of polarised Th cells. For example, blocking ICOS alone had a 
limited but significant capacity to downregulate Th subset development upon infection 
with lymphocytic choriomeningitis virus (LCMV) and vesicular stomatitis virus (VSV). 
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ICOS inhibition in the absence of CD28 further reduced Th1/Th2 polarisation (Kopf et 
al., 2000). In a clinical model of experimental autoimmune myasthenia gravis (EAMG), 
ICOS deficiency conferred resistance to disease development, blunted lymphocyte 
proliferation and both Th1 and Th2 differentiation (Scott et al., 2004). A separate study 
found that Th1-mediated acute GVHD was inducible despite ICOS deficiency but not 
Th2-mediated chronic GVHD, suggesting the expression levels of ICOS are critical for 
determining the polarisation of Th cell function (Watanabe et al., 2006). A concept that 
has increasingly gained traction is one in which ICOS is not involved in dictating polarity 
of the Th response but regulates instead the expansion of Th subsets. ICOS-deficient 
mice infected with Trichuris muris or Toxoplasma gondii exhibited delay in protective 
immunity that was associated with a defect in infection-induced increases in the number 
of activated and proliferating CD4+ T cells (Wilson et al., 2006). Two separate studies 
examining the role of ICOS in transplantation immunity showed its importance in 
expanding allogeneic donor T cells. In a vascularised mouse cardiac allograft model, 
ICOS blockade suppressed alloreactive CD4+ T cell expansion and alloantibody 
production (Harada et al., 2003) while similar blockade during allogeneic bone marrow 
engraftment inhibited expansion of GVHD-causing effector T cells in secondary 
lymphoid and GVHD target organs (Taylor et al., 2005). 
The complex function of ICOS in Th1- and Th2-mediated immunity revealed by 
the above findings prompted us to investigate whether ICOS is differentially regulated in 
Th1 and Th2 cells and if so, to decipher the mechanisms involved. We first showed, after 
differentiating naïve Th cells under Th0, Th1 and Th2-polarising conditions, that ICOS is 
expressed highest in terminally differentiated Th2, lowest in Th0 and intermediate 
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between the two in Th1 cells. In addition, ectopic expression of T-bet and GATA-3 could 
enhance ICOS expression both in EL4 as well as in primary CD4+ T cells and co-
expression of NFATc2 led to synergy with either of them to enhance ICOS expression in 
the correct differentiating lineage. Hence, T-bet and GATA-3, along with NFATc2, 
which was previously demonstrated to drive ICOS transcription during the early phase of 
TCR/CD28-mediated stimulation, play important roles in driving ICOS expression in 
Th1 and Th2 cells. 
The critical roles of T-bet and GATA-3 in the control of Th1 and Th2 lineage-
associated cytokine genes have been well documented. For instance, T-bet is known to 
activate the transcription of ifn-γ through binding its promoter and enhancer (Lee et al., 
2004a; Shnyreva et al., 2004) while GATA-3 is known to regulate the IL-4, -5 and -13 
cytokine cluster (Murphy and Reiner, 2002; Zhou and Ouyang, 2003). On the other hand, 
NFATc2 has been shown to bind the ifn-γ 5′ conserved noncoding sequences and 
promoter in Th1 cells and the il-4 enhancer in Th2 cells (Agarwal et al., 2000; Lee et al., 
2004a). In this study, we showed that a single costimulatory gene, icos, is regulated by 
both T-bet and GATA-3 via distinct mechanisms in Th cells, with the former acting on 
the promoter while the latter via a 3′UTR element of icos. 
What role might ERK signalling, shown in the first part to be critical for initiating 
ICOS transcription during TCR/CD28-mediated activation, have in the regulation of 
ICOS transcription during Th cell differentiation? The nuclear activity of ERK is induced 
more rapidly in developing Th1 compared to Th2 cells, raising the possibility that ERK 
signalling may play a dominant role in ICOS regulation in Th1 compared to Th2 cells, at 
least during the developing phase. Consistent with this, enhanced ERK activity in 
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terminally differentiated T-bet-/- Th1 cells may compensate somewhat for the loss of T-
bet in driving ICOS mRNA levels in these cells (Figure 3.11B). ERK has been reported 
to stabilise GATA-3 protein (possibly through Ser/Thr phosphorylation) by preventing its 
Mdm2-mediated and ubiquitin-dependent proteasomal degradation in polarised Th2 cells 
(Yamashita et al., 2005). We think that such a mechanism does not sufficiently account 
for high ICOS transcription in Th2 cells, as pharmacological inhibition of ERK activity 
by U0126 in these cells led to virtually no effects on ICOS mRNA levels (data not 
shown). Hence, although efficient TCR-mediated activation of calcineurin-NFAT and the 
Ras-ERK MAPK signalling cascades are required for Th2 differentiation (Yamashita et 
al., 1999; Yamashita et al., 2000), the function of ERK in Th2-specific ICOS 
transcription remains unclear. 
Separately, NF-κB has also been demonstrated to play a critical role in GATA-3 
protein expression and Th2 differentiation in a mouse model of allergic airway 
inflammation (Das et al., 2001). Specifically, p50-/- mice failed to induce GATA-3 
expression under Th2-differentiating conditions but showed intact T-bet expression and 
IFN-γ production under Th1-polarising conditions. Moreover, developing but not already 
committed Th2 cells pretreated with SN50 (an NF-κB competitor peptide) but not a 
mutant peptide prevented nuclear translocation of NF-κB and abolished GATA-3 binding 
to its specific motif(s) on the IL-5 promoter. This, together with the presence of putative 
NF-κB binding sites on the GATA-3 promoter, raises the possibility that inhibiting 
NF-κB activity in Th2 cells may also block ICOS up-regulation in these cells, although 
we observed no such effect on ICOS induction in SN50-treated Th2 cells (data not 
shown). Given that GATA-3 is subjected to multiple levels of transcriptional and 
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translational control, this likely precludes a straightforward interpretation of results 
yielded by simply treating developing Th2 cells with SN50 and assessing ICOS mRNA 
expression. 
SAP (SLAM-associated protein) couples Fyn to SLAM (Signalling Lymphocyte 
Activation Molecule) receptors in T and NK cells (Latour and Veillette, 2004; Chan et 
al., 2003) and a loss-of-function mutation or deletion of sh2d1a, the gene encoding SAP, 
is responsible for the pathogenesis of X-linked lymphoproliferative syndrome (XLP) or 
Duncan’s disease in humans upon primary Epstein-Barr virus (EBV) infection, leading to 
significant mortality (Engel et al., 2003). While mice lacking expression of SAP 
recapitulate several features of XLP following viral infection (Czar et al., 2001; Wu et al., 
2001), mice expressing a Fyn-binding mutant of SAP phenocopy SAP deficient mice in 
terms of defective Th2 cytokine production and impaired TCR-mediated induction of 
GATA-3 (Cannons et al., 2004; Davidson et al., 2004). In particular, when naïve Th cells 
from SAP and Fyn-/- mice were stimulated using anti-CD3 and/or anti-CD28 Abs, 
GATA-3 transcript levels were markedly reduced as compared to WT cells. Furthermore, 
human XLP CD4+ T cells failed to up-regulate ICOS expression efficiently upon 
stimulation (Ma et al., 2005), resulting in insufficient IL-10 production and contributing 
to hypogammaglobulinemia. This, together with our earlier work which identified Fyn to 
be the upstream kinase activating NFATc2 and subsequent ICOS transcription, led us to 
hypothesise that a SAP-Fyn-GATA-3 pathway may operate to drive high levels of ICOS 
transcription in Th2 cells. However, retroviral reconstitution of the Fyn-binding mutant 
of SAP in SAP deficient CD4+ T cells rescued successfully the SAP-associated defects in 
ICOS expression and humoral responses, but preserved the Th2 cytokine defects 
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(Cannons et al., 2006). This suggests that SAP likely mediates ICOS up-regulation via 
yet to be discovered signalling pathway(s) independent of its Fyn-binding function. 
Consistent with this, inhibition of Fyn signalling by the broad Src family kinase inhibitor 
PP2 in developing Th2 cells had modest effects on cell surface ICOS expression in these 
cells (data not shown). 
It is becoming increasingly appreciated that besides the classical mechanism of 
trans-acting transcription factors binding to cis-regulatory DNA regions to activate or 
repress gene transcription, epigenetic modifications at the chromatin level are essential to 
initiate and maintain transcriptional permissiveness or silencing. In differentiating Th 
cells, antigen receptor and cytokine signals act in synergy to drive reciprocal activation 
and silencing of the IFN-γ and IL-4 cytokine gene loci, alterations which are heritably 
maintained in maturing Th1 or Th2 cells and their progeny. Unpolarised transcription and 
chromatin remodelling of the cytokine genes in naïve Th cells is followed by 
consolidation of epigenetic changes and the establishment of self-reinforcing 
transcription factor networks in differentiated Th cells (Ansel et al., 2003). Among the 
epigenetic changes in chromatin structure are changes in nucleosome positioning and 
conformation; changes in the histone content of nucleosomes; and changes in 
modification status of histones and DNA. The amino tails of histones, as well as some 
internal sites, are amenable to a large array of covalent modifications including 
phosphorylation, acetylation, methylation and ubiquitination. This relates to another 
interesting finding in our study: the dynamic manner in which the broadly expressed 
NFATc2 partners with Th-restricted T-bet or GATA-3 to drive icos transcription. In the 
first 2 days of differentiation, NFATc2 activates icos transcription non-selectively 
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through its promoter, but not 3′UTR, in all Th lineages. As Th cells commit to their 
developmental fate, NFATc2 cooperates with T-bet via the promoter and GATA-3 via a 
3′UTR element to induce ICOS expression in Th1 and Th2 cells, respectively. The 
binding pattern of T-bet/NFATc2 complex to the icos promoter and GATA-3/NFATc2 to 
the 3′UTR element coincides precisely with the chromatin accessibility of these 
regulatory regions as Th cells mature, as assessed by the trimethylation of histone 3 
lysine 4. Histone trimethylation correlates with accessible or active gene loci (Lachner 
and Jenuwein, 2002) and is a more stable and reliable marker of active transcription than 
histone acetylation (Bannister et al., 2002). Such a process is likely to be carried out by 
histone methyltransferases, whereas the role of the converse process, histone 
demethylation, in reversing chromatin accessibility at icos regulatory regions in the 
appropriate Th cell subset remains to be explored. Downstream of STAT-1, T-bet is 
proposed to induce chromatin remodelling of the initially repressed IFN-γ locus in 
developing Th1 cells, resulting eventually in acute transcription when the cells become 
more Th1-committed (Mullen et al., 2001). Similarly, in developing Th2 cells, GATA-3, 
acting downstream of STAT-6, induces heritable remodelling of the il-4 locus (Ouyang et 
al., 1998; Takemoto et al., 2000). GATA-3 also induced IL-4-independent changes of the 
chromatin structure, specifically histone acetylation, at the il-10 locus, but did not 
transactivate the il-10 promoter despite being recruited in vivo to two locations on 
the il-10 locus (Shoemaker et al., 2006). Whether T-bet or GATA-3 participates similarly 
in promoting transcriptional competency of the icos promoter or 3′UTR, in addition to 
directly transactivating it, is an open question. Nevertheless, it is highly likely that 
chromatin remodelling of the regulatory regions of icos, like those of cytokine genes, and 
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the consequent DNA-association patterns of T-bet/NFATc2 and GATA-3/NFATc2 were 
conditioned by the combined action of TCR-mediated signalling and polarising cytokines 
responsible for moulding Th identity. 
Another example of chromatin modification providing exquisite specification of 
transcriptional competency is the superinduction of IL-10 production by macrophages 
stimulated in the presence of immune complexes. In resting cells, which make essentially 
no cytokines, the il-10 promoter is associated with histones containing little or no 
detectable modifications. Pharmacologically inhibiting activated ERK abolished rapid 
and dynamic phosphorylation of serine 10 on H3 (H3ser10) at specific sites on the il-10 
promoter, decreasing its accessibility to transcription factors generated in response to 
stimulation. A histone phosphorylation event was critical to efficiently induce il-10 gene 
expression in macrophages, thus defining a unique way in which the expression of a 
cytokine gene is regulated in macrophages (Lucas et al., 2005; Zhang et al., 2006). It is 
plausible that a similar mechanism may operate at the icos promoter during Th1 
differentiation, consistent with the more rapid dynamics of nuclear ERK accumulation in 
Th1 compared to Th2 cells. In agreement with ERK being recruited to chromatin and 
transcribed regions of genes, a recent report described the physical interaction of most 
MAPKs and protein kinase A subunits with the genes that they regulated, although in the 
yeast (Saccharomyces cerevisiae) genome (Pokholok et al., 2006). 
A central role for ICOS in GC formation and effective development of humoral 
immunity has been well documented (Dong et al., 2001b; McAdam et al., 2001; Shilling 
et al., 2006; Tafuri et al., 2001). TFH cells constitute an important part of the GC reaction 
and express high levels of ICOS, SAP, SLAM and CD84 mRNA (Chtanova et al., 2004; 
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Vinuesa et al., 2005a). These cells help GC B cells class-switch and differentiate into 
plasma cells. Given the unique CXCR5+ and IL-21-secreting signature of TFH cells that 
partly distinguishes them from IFN-γ-producing Th1 and IL-4-producing Th2 cells, it 
will be intriguing to elucidate the signalling pathways and transcription factors that 
regulate ICOS expression in these cells, bearing in mind the much greater phenotypic 
overlap between TFH and Th2 compared to Th1 cells. NFATc2 was shown to bind and 
directly activate the il-21 promoter in Th2 cells, while T-bet represses IL-21 transcription 
by inhibiting binding of NFATc2 to the same promoter in Th1 cells (Mehta et al., 2005), 
suggesting NFATc2 may feature crucially in TFH-specific ICOS regulation. Of course, a 
major caveat is the technical difficulty in distinguishing between cells of the TFH and Th2 
lineages, and subsequently determining which aspects of ICOS regulation are specific to 
each lineage. 
Our data so far indicate that the cytokine networks and transcriptional apparatus 
initiating and reinforcing Th lineage commitment appear to instruct ICOS expression in a 
Th-specific manner which, together with earlier work demonstrating roles for ICOS in Th 
subset polarisation (Kopf et al., 2000) and the transcriptional control of Th2 
differentiation (Nurieva et al., 2003a), provide the basis for feed forward amplification 
linking ICOS expression and Th cell differentiation (Figure 4.2A and B). Of course, Th1 
and Th2 cells are by no means the only Th cell subsets found in the adaptive immune 
system. The concept of Th differentiation, based on the traditional Th1/Th2 dichotomy, 
has been under intense scrutiny and subjected to major revisions in recent years, 
introducing new complexities into the field of T cell biology. The list of possible Th cell 
subsets has grown to include Treg (which can be further categorised into natural or 
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inducible Treg, the latter comprising partly Tr1 and Th3 subpopulations), the follicular 
helper T (TFH), IL-17-producing Th17 and the speculative IL-25-producing Th25 lineages 
(Tato et al., 2006). All these Th lineages likely express or can be induced to express 
ICOS. However, it is presently unclear how the level of ICOS expression compare 
between lineages and if T-bet, GATA-3 or other transcription factors regulate ICOS 
expression via different pathways in these subsets. Consider the example of Th17 cells, 
which have been causally linked to several inflammatory and autoimmune diseases 
including collagen-induced arthritis and experimental autoimmune myasthenia gravis, the 
pathogeneses of which were reportedly dependent on ICOS (Iwai et al., 2002; Scott et al., 
2004). Both CD28 and ICOS were found to be required for the generation of effector 
CD4+ T cells that produce IL-17 (Park et al., 2005). However, data accumulated so far 
suggest that the Th17 developmental pathways are independent of STAT-1/4 and T-bet as 
well as STAT-6 and GATA-3, which are required respectively for Th1 and Th2 
differentiation. Are T-bet and GATA-3 therefore dispensable for Th17-intrinsic 
regulation of ICOS? A very recent study reported surface ICOS expression to be higher 
in Th17 compared to Th1 cells (Nakae et al., 2007), suggesting NFATc2 and ERK 
signalling may contribute more substantially to and/or unknown factors other than T-bet 
and GATA-3 direct ICOS regulation in this cell type. Combined actions of the pleiotropic 
TGF-β and pro-inflammatory IL-6 cytokines were shown to induce Th17 development 
(Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006), while the retinoic acid-
related orphan receptor ROR-γt was established as necessary and apparently sufficient for 
Th17 commitment (Ivanov et al., 2006). What is the extent of contribution, if any, by 
these factors to ICOS expression in the Th17 lineage? Besides Th17 cells, what possible 
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mechanisms underlie ICOS regulation in Treg cells, particularly in the 




Figure 4.2 Model of feed-forward regulatory circuits linking ICOS expression, 
cytokine networks and transcriptional machinery directing A, Th1 and B, Th2 cell 
differentiation. 
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4.3 Post-transcriptional regulation of ICOS by E3 ubiquitin ligase, roquin 
Apart from regulation at the transcriptional level, post-transcriptional mechanisms 
may also govern ICOS expression. As mentioned before, in sanroque mice carrying a 
mutated Rc3h1 gene encoding for the roquin protein, TFH cells hyper-proliferated and GC 
development was exacerbated, and these mice eventually succumbed to autoimmune 
disease (Vinuesa et al., 2005a), which emphasises the potential importance of TFH cells in 
regulating autoantibody production and autoimmune pathogenesis (Vinuesa et al., 
2005b). Importantly, sanroque CD4+ T cells expressed higher levels of ICOS compared 
to their wildtype counterparts, suggesting roquin may play a role in limiting ICOS 
expression. Roquin possesses amino-terminal RING-1 and CCCH zinc finger domains, 
the former being shared by E3 ubiquitin ligases and the latter by RNA-binding proteins 
such as Tristetraprolin (TTP). TTP is known to bind to the 3′UTR of target genes and 
facilitate the processing, stabilisation and translation of their mRNAs. For example, SAP 
mRNA contains AUUUA sequences in the 3′UTR that are targeted for ubiquitin-
dependent degradation by RNA binding proteins such as AUF1 and HuR (Okamoto et al., 
2004b). It is therefore conceivable that roquin may modulate ICOS expression post-
transcriptionally through affecting mRNA and/or protein stability. 
We show that roquin plays a nontrivial role in regulating ICOS expression at the 
post-transcriptional level. In particular, roquin WT, but not M199R mutant, efficiently 
limited ICOS mRNA levels in EL4 cells, suggesting that the ROQ domain of roquin is in 
part important for fulfilling this role. We also observed that icos transcripts in EL4 cells 
over-expressing roquin WT decayed with faster kinetics than in cells bearing null vector 
control, suggesting roquin negatively regulates ICOS mRNA stability and elucidating a 
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novel pathway by which ICOS expression is modulated. Consistent with roquin being a 
negative regulator of ICOS expression, we found roquin mRNA to be expressed highest 
in Th0, followed by Th1 and Th2 cells (data not shown). Via what mechanisms roquin 
exerts its effects on ICOS mRNA and if these mechanisms are Th-specific are 
unanswered questions that will be the subject of future research. 
 
4.4 Conclusion 
Our results have indicated that the initial TCR/CD28-dependent regulation of 
ICOS is mediated by Fyn-calcineurin-NFATc2 and MEK2-ERK1/2 signalling. As Th 
cells differentiate along separate lineages under the increasing influence of polarising 
cytokines and Th-associated transcriptional machinery, TCR-responsive NFATc2 induces 
ICOS transcription during the early stage of Th development, followed by Th-specific 
determination of the ICOS expression signature by STAT-responsive T-bet and GATA-3 
as differentiation progresses to the terminal stage. What these results appear to inform is 
a possible model in which the early induction of ICOS in TCR/CD28-stimulated naïve Th 
cells is important to some extent in determining Th polarity, depending on the 
pathological context. When the dominant Th response is established, ICOS expression 
may be modulated according to requirements for its signalling in Th1- and Th2-mediated 
immune responses. As noted earlier, ICOS is expressed at high levels in TFH and IL-10-
producing Treg cells, consistent with its crucial roles in facilitating TFH cell help for B cell 
antibody class-switching in GCs and T cell-mediated tolerance, respectively. Because 
ICOS is implicated in the immunopathogenesis of a myriad of infectious, inflammatory 
and autoimmune diseases, understanding the mechanisms that govern its expression in 
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the various Th subsets that play differential roles in disease development may shed light 
on how to manipulate and fine-tune the T cell response toward desirable therapeutic 
outcomes, with the objective of improving host immunity whilst avoiding autoimmunity. 
We propose that transcriptional mechanisms are important to rapidly induce ICOS 
expression in naïve host T cells activated by antigen-stimulated APCs during the early 
phase of the immune response against pathogens, whereas post-transcriptional 
mechanisms are important for repressing ICOS mRNA or protein levels following 
immune clearance of the pathogen, the failure of which can lead to prolonged T cell 
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